Veterinary Drug terms — page 16 | HESTIA Glossary

Browse all 1,061 veterinary drug terms HESTIA uses to describe agricultural data — with definitions and synonyms. Free and open.

Oxymetazoline 3-[(4,5-Dihydro-1H-imidzol-2-yl)methyl]-6-(1,1-dimethylethyl-2,4-dimethylphenol; Oxymetazoline; H 990
Oxymetholone oxymetholone; 434-07-1; Nastenon; Protanabol; Anadrol; OximetoloAnadrol-50; Oxymethalone; Oxymethenolone; Anapolon; Anasteron; Plenastril; Synasteron; Adroyd; Oximetalonu; Oximetholonum; Oxymetholonum; Adroidin; Anadroyd; Becorel; Dynasten; Methabol; Pavisoid; Roboral; Zenalosyn; Oxitosona-50; Anapolon 50; Ossimetolone [DCIT]; CI-406; Anasteronal; Oximetholone; UNII-L76T0ZCA8K; Oximetolona [INN-Spanish]; Oxymetholonum [INN-Latin]; Anasterone; CCRIS 492; HSDB 3374; EINECS 207-098-6; CI 406; 17-Hydroxy-5-alpha-androstan-3-one; NSC-26,198; 2-Hydroxymethylene-17alpha-methyldihydrotestosterone; L76T0ZCA8K; Pardroyd; HMD; 4,5alpha-Dihydro-2-hydroxymethylene-17alpha-methyltestosterone; 17alpha-Methyl-2-hydroxymethylene-17-hydroxy-5alpha-androstan-3-one; 2-Hydroxymethylene-17alpha-methyl-5alpha-androstan-17beta-ol-3-one; 17-Hydroxy-2-(hydroxymethylene)-17-methyl-5-alpha-17-beta-androst-3-one; 17beta-Hydroxy-2-(hydroxymethylene)-17-methyl-5alpha-androstan-3-one; 2-Hydroxymethylene-17alpha-methyl-17beta-hydroxy-5alpha-androstan-3-one; 2-Hydroxymethylene-17-alpha-methyl-dihydrotestosterone; NCGC00091430-01; 2-Hydroxymethylene-17alpha-methylandrostan-17beta-ol-3-one; 4,5-Dihydro-2-hydroxymethylene-17-alpha-methyltestosterone; 2-Hydroxymethylene-17alpha-methyl-17beta-hydroxy-3-adrostanone; 17-beta-Hydroxy-2-hydroxymethylene-17-alpha-methyl-3-androstanone; 2-Hydroxymethylene-17-alpha-methyl-17-beta-hydroxy-3-androstanone; Oxymetholone [Androgenic steroids, anabolic]; 17-alpha-Methyl-2-hydroxymethylene-17-hydroxy-5-alpha-androstan-3-one; 2-Hydroxymethylene-17-alpha-methyl-5-alpha-androstan-17-beta-ol-3-one; 5alpha-Androstan-3-one, 17beta-hydroxy-2-(hydroxymethylene)-17-methyl-; 17-beta-Hydroxy-2-(hydroxymethylene)-17-alpha-methyl-5-alpha-androstan-3-one; Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (alpha,17beta)-; Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5alpha,17beta)-; DSSTox_GSID_23794; Ossimetolone; 17-Hydroxy-2-(hydroxymethylene)-17-methyl-5-androstan-3-one; Hydroxymetholone; 5-alpha,17-beta-Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-; (2Z,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2-(hydroxymethylidene)-10,13,17-trimethyl-1,4,5,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one; CAS-434-07-1; DSSTox_CID_3794; DSSTox_RID_77193; Oxymetholone [USAN:INN:BAN:JAN]; Anadrol-50 (TN); Oxymetholone [USAN:USP:INN:BAN:JAN]; SCHEMBL145158; SCHEMBL145160; CHEBI:7864; CHEMBL1200585; DTXSID5023794; NIOSH/BV8059400; Oxymetholone (JP17/USP/INN); LS-50; Tox21_111131; Tox21_200071; BDBM50248303; MFCD00869395; AKOS027473312; Tox21_111131_1; ZINC118912450; ACN-031988; DB06412; NCGC00091430-02; NCGC00257625-01; NCGC00263581-01; CC-33433; NS-05498; BV80594000; C07393; D00490; 2-hydroxymethylene-17a-methyl dihydrotestosterone; AB01566927_01; Q420864; W-106231; 17b-hydroxy-2-hydroxymethylene-17a-methyl-3-androstanone; 2-Hydroxymethyleneandrostan-17-beta-ol-17-alpha-methyl-3-one; 17beta-Hydroxy-2-hydroxymethylidene-17alpha-methyl-3-androstanone; 2-hydroxymethylene-17alpha-methyl-17beta-hydroxy-3-androstanone; 17-hydroxy-2-(hydroxymethylene)-17-methyl-5alpha,17beta-a ndrostan-3-one; 17-hydroxy-2-(hydroxymethylene)-17-methyl-5alpha,17beta-androstan-3-one; 17-hydroxy-2-(hydroxymethylene)-17-methyl-5alpha-17beta-androst-3-one; 17alpha-Methyl-2-hydroxymethylene-17beta-hydroxy-5alpha-androstan-3-one; 17beta-hydroxy-2-(hydroxymethylene)-17alpha-methyl-5alpha-androstan-3-one; 17beta-hydroxy-2-(hydroxymethylidene)-17-methyl-5alpha-androstan-3-one; 5-alpha-Androstan-3-one, 17-beta-hydroxy-2-(hydroxymethylene)-17-methyl-; Androstan-3-one, 17-beta-hydroxy-2-(hydroxymethylene)-17-alpha-methyl-; androstano[2,3-c][1,2,5]oxadiazol-17-ol, 17-methyl-, (5alpha,17beta)-; (2Z,5alpha,17beta)-17-Hydroxy-2-(hydroxymethylene)-17-methylandrostan-3-one; (2Z,5alpha,17beta)-17-Hydroxy-2-(hydroxymethylidene)-17-methylandrostan-3-one; (5alpha,17beta)-17-hydroxy-2-(hydroxymethylidene)-17-methylandrostan-3-one; 5-alpha-Androstan-3-one, 17-beta-hydroxy-2-(hydroxymethylene)-17-methyl- (8CI); androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-met hyl-,(5alpha,17beta)-; Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5-alpha,17-beta)-; Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5-alpha,17-beta)- (9CI); androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-,(5alpha,17beta)-; Androstano(2,3-c)(1,2,5)oxadiazol-17-ol, 17-methyl-, (5-alpha,17-beta)-; Androstano(2,3-c)(1,2,5)oxadiazol-17-ol, 17-methyl-, (5-alpha,17-beta)- (9CI); (1S,2S,4Z,7S,10R,11S,14S,15S)-14-hydroxy-4-(hydroxymethylidene)-2,14,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-5-one; (1S,3aS,3bR,5aS,8Z,9aS,9bS,11aS)-1-hydroxy-8-(hydroxymethylidene)-1,9a,11a-trimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-7-one; (5S,8R,9S,10S,13S,14S,17S,Z)-17-hydroxy-2-(hydroxymethylene)-10,13,17-trimethylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one; Adroidin
Oxytetracycline 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-; CAS-79-57-2; 4-14-00-02633; 5-Hydroxytetracycline; Adamycin; Antibiotic TM 25; Berkmycen; Biostat; Biostat PA; BRN 2714587; Dabicycline; EINECS 201-212-8; Fanterrin; Geomycin; Geomycin (Streptomyces vimosus); Geotilin; HSDB 3145; Imperacin; LA 200; Lenocycline; Liquamycin; Liquamycin LA 200; Macocyn; Mycoshield TMQTHC 20; NCI-C56473; NSC-9169; Oksisyklin; Ossitetraciclina; Ossitetraciclina [DCIT]; OTC; OTC (antibiotic); Oxitetraciclina; Oxitetracyclin; Oxitetracyclinum; Oxy-kesso-tetra; Oxymycin; Oxymykoin; Oxypam; Oxysteclin; Oxyterracin; Oxyterracine; Oxyterracyne; Oxytetracyclin; Oxytetracycline; Oxytetracycline amphoteric; Oxytetracyclinum; Pennox 200; Proteroxyna; Riomitsin; Ryomycin; Solkaciclina; Stevacin; Tarocyn; Tarosin; Teravit; Terrafungine; Terramicina Oftalmica; Terramitsin; Terramycin; Terramycin im; Terramycin Q50; Tetrachel; Tetracycline, 5-hydroxy-; Tetran; UNII-SLF0D9077S; Ursocyclin; Ursocycline; Vendarcin
Paclitaxel (alpha-R,betaS)-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester; Paclitaxel; (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
Palmitoleic acid AI3-36443
Palygorskite Palygorskite; Attapulgite,activated; Attapulgite (activated); DB01574; Aluminium magnesium silicate (attapulgite); Q414065; Attapulgite; X 250
Papaverine 1-[(3,4-Dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline; papaverine; Papaverin; Papanerine; Robaxapap; 58-74-2; Papanerin; Pavabid; Papaverina; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline; Papaverine [BAN]; 6,7-Dimethoxy-1-veratrylisoquinoline; Papaverina [Italian]; NSC 136630; UNII-DAA13NKG2Q; Isoquinoline, 6,7-dimethoxy-1-veratryl-; S-M-R; Papaverine (BAN); 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline; 1-((3,4-Dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline; EINECS 200-397-2; DAA13NKG2Q; Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-; BRN 0312930; 1-(3,4-Dimethoxy-benzyl)-6,7-dimethoxy-isoquinoline; CHEMBL19224; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-isoquinoline; 4-[(6,7-Dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene; Pavatym; CHEBI:28241; HSDB 3147; Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-; XQYZDYMELSJDRZ-UHFFFAOYSA-N; NSC-136630; Pavacot; 6,7-DIMETHOXY-1-(3.4-DIMETHOXYBENZYL)-ISOQUINOLINE; Ceraspan; Mesotina (TN); EV1; NSC35443; CAS-61-25-6; NCGC00015810-02; 2wey; RS 47; TNP00305; Spectrum_000071; Prestwick0_000583; Prestwick1_000583; Prestwick2_000583; Prestwick3_000583; Spectrum2_000978; Spectrum3_000537; Spectrum4_000467; Spectrum5_001188; Lopac-P-3510; Isoquinoline, 6,7-dimethoxy-1-veratryl-(8Cl); Lopac0_000957; Oprea1_387689; Oprea1_810508; SCHEMBL34702; BSPBio_000426; BSPBio_002153; KBioGR_000914; KBioSS_000471; 5-21-06-00182 (Beilstein Handbook Reference); DivK1c_000321; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline; SPBio_001015; SPBio_002645; BPBio1_000470; MEGxp0_001880; DTXSID4023418; ACon1_000238; ACon1_002094; BDBM14754; CTK7A7298; KBio1_000321; KBio2_000471; KBio2_003039; KBio2_005607; KBio3_001653; KS-00002WWI; ZINC56555; 1-[(3,4-Dimethoxyphenyl)methyl]6,7-dimethoxyisoquinoline; NINDS_000321; HMS3561N11; HMS3746M21; ALBB-010475; 1-{[3,4-bis(methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline; BBL012345; NSC136630; STK039035; Isoquinoline,7-dimethoxy-1-veratryl-; AKOS000277460; API0003747; CCG-202821; CS-7800; DB01113; KS-5336; MCULE-9598291893; SDCCGMLS-0003037.P003; SDCCGSBI-0050931.P005; IDI1_000321; NCGC00015810-01; NCGC00015810-03; NCGC00015810-04; NCGC00015810-05; NCGC00015810-06; NCGC00015810-07; NCGC00015810-08; NCGC00015810-09; NCGC00015810-13; NCGC00024428-03; NCGC00024428-04; HY-18077; LS-85584; NCI60_003183; ST023301; SBI-0050931.P004; DB-053252; AB00053515; FT-0631261; R1247; Y1354; 6,7-DI-METHOXY-1-VERATRYLISOQUINOLINE; C06533; D07425; AB00053515_14; Isoquinoline, 6,7-dimethoxy-1-veratryl- (8CI); WLN: T66 CNJ B1R CO1 DO1& HO1 IO1; Q410374; 6,7-dimethoxy-1-veratryl-isoquinoline; hydrochloride; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline #; BRD-K15567136-001-01-1; BRD-K15567136-003-06-6; BRD-K15567136-003-18-1; Isoquinoline,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-; SR-01000003098-10; InChI=1/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H; Papaverine; 5-21-06-00182 (Beilstein Handbook Reference)
Parachlorophenol 4-Chlorophenol; 4-CHLOROPHENOL; p-Chlorophenol; 106-48-9; parachlorophenol; Phenol, 4-chloro-; 4-Hydroxychlorobenzene; Phenol, p-chloro-; Applied 3-78; 4-Monochlorophenol; p-Chlorophenic acid; p-Chlorfenol; 4-Chloro-1-hydroxybenzene; p-Chlorfenol [Czech]; 4-Chlorphenol; 4-chloro-phenol; Parachlorophenol [USP]; NSC 2877; UNII-3DLC36A01X; CCRIS 642; HSDB 1414; C6H5ClO; EINECS 203-402-6; Parachlorophenol (JAN/USP); AI3-19422; 3DLC36A01X; CHEBI:28078; WXNZTHHGJRFXKQ-UHFFFAOYSA-N; MFCD00002318; NCGC00090814-01; 4-Chlorophenol, 99+%; DSSTox_CID_1871; DSSTox_RID_76376; DSSTox_GSID_21871; p-Chlorophenol, liquid [UN2021] [Keep away from food]; p-Chlorophenol, solid [UN2020] [Keep away from food]; CAS-106-48-9; 4chlorophenol; p-chloro phenol; para-chlorophenol; parachloro phenol; 4-chloro phenol; 4-chloranylphenol; 4CH; Parachlorophenol,(S); p-Chlorophenol, solid; p-Chlorophenol, liquid; PubChem22009; Spectrum_000939; Spectrum2_000968; Spectrum3_000539; Spectrum4_000468; Spectrum5_001228; PARA CHLORO PHENOL; CHLOROPHENOL(4-); WLN: QR DG; 4-ClC6H4OH; ACMC-2098jw; bmse000461; EC 203-402-6; 4-Chlorophenol, >=99%; SCHEMBL28864; BSPBio_002157; KBioGR_000916; KBioSS_001419; KSC174K7J; MLS002454432; BIDD:ER0011; CHEMBL57053; DivK1c_000310; SPECTRUM1500460; SPBio_000975; PARAGOS 390356; ZINC1885; DTXSID1021871; BDBM36299; CTK0H4574; HMS500P12; KBio1_000310; KBio2_001419; KBio2_003987; KBio2_006555; KBio3_001657; KS-00000VEZ; RARECHEM FH 2C 0018; TIMTEC-BB SBB040864; NSC2877; NINDS_000310; OTAVA-BB 1506172; HMS1920F08; HMS2091N08; HMS2230B13; HMS3373O02; LABOTEST-BB LTBB002362; Pharmakon1600-01500460; 1-CHLORO-4-HYDROXY-BENZENE; NSC-2877; AKOS BBS-00004332; Tox21_111028; Tox21_201704; Tox21_302860; ANW-15354; CCG-40184; LS-401; NSC757263; SBB040864; STL194293; 4-Chlorophenol, for synthesis, 98%; AKOS000118967; Tox21_111028_1; AS00215; DB13154; MCULE-4022476067; MP-2149; NSC-757263; RTR-013097; TRA0010400; IDI1_000310; NCGC00090814-02; NCGC00090814-03; NCGC00090814-04; NCGC00090814-05; NCGC00090814-07; NCGC00256497-01; NCGC00259253-01; 4-Chlorophenol 10 microg/mL in Methanol; SC-19124; SMR001252242; 4-Chlorophenol 100 microg/mL in Methanol; SBI-0051474.P003; AB1003203; DB-028832; ST2411367; 4-Chlorophenol, puriss., >=99.0% (GC); CS-0005709; FT-0618238; ST50214454; 4-Chlorophenol 100 microg/mL in Isopropanol; 4-Chlorophenol 1000 microg/mL in Isopropanol; C02124; D00149; 93919-EP2269977A2; 93919-EP2272509A1; 93919-EP2277858A1; 93919-EP2284157A1; 93919-EP2298743A1; 93919-EP2298747A1; 93919-EP2298750A1; 93919-EP2305625A1; AB00052066_06; 148113-EP2269977A2; 148113-EP2280005A1; 148113-EP2289884A1; 4-Chlorophenol, PESTANAL(R), analytical standard; SR-05000001691; J-001599; Q2179668; SR-05000001691-1; BRD-K40992116-001-05-5; F0001-0124; p-Chlorophenol, liquid [UN2021] [Keep away from food]; p-Chlorophenol, solid [UN2020] [Keep away from food]; Z1262246118; 1-CHLORO-1-(4-CHLOROPHENOXY)-3,3-DIMETHYLBUTANONE; UNII-AZ1041M258 component WXNZTHHGJRFXKQ-UHFFFAOYSA-N; UNII-E9JIO40PSX component WXNZTHHGJRFXKQ-UHFFFAOYSA-N; 1-(4-CHLOROPHENOXY)-1-CHLORO-3,3-DIMETHYL-2-BUTANONE; InChI=1/C6H5ClO/c7-5-1-3-6(8)4-2-5/h1-4,8; Parachlorophenol, United States Pharmacopeia (USP) Reference Standard; 4-Chlorophenol solution, 725 mg/L in H2O, for AOX determination (according to DIN 38409-H14); p-Chlorophenol; AI3-19422
Parnate trans-(+-)-2-Phenylcyclopropanamine; Tranylcypromine; 3-12-00-02797 (Beilstein Handbook Reference)
Paromomycin O-2,6-Diamino-2,6-dideoxy-beta-L-idopyranosyl-(1->3)-O-beta-D-ribofuranosyl-(1->5)-O-[2-amino-2-deoxy-alpha-D-glucopyranosyl-(1->4)]-2-deoxy-D-streptamine; Paromomycin; R 400
Paromomycin sulphate O-2,6-Diamino-2,6-dideoxy-beta-L-idopyranosyl-(1->3)-O-beta-D-ribofuranosyl-(1->5)-O-[2-amino-2-deoxy-alpha-D-glucopyranosyl-(1->4)]-2-deoxy-D-streptamine sulfate (1:?); Paromomycin sulfate [USP:JAN]; Aminosidin sulfate
Paroxetine (3S,4R)-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; paroxetine; 61869-08-7; Paxil; Paxil CR; Paxetil; Seroxat; Frosinor; ParoxetiParoxetinum; Casbol; Motivan; Aropax; Paroxetinum [INN-Latin]; PaxPar; Paroxetina [INN-Spanish]; BRL 29060; FG 7051; Pexeva; BRL-29060; Paroxetine [USAN:INN:BAN]; (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine; (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; UNII-41VRH5220H; (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine; (3s,4r)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; [3H]Paroxetine; C19H20FNO3; FG-7051; CHEMBL490; CHEBI:7936; 41VRH5220H; 110429-35-1; DSSTox_CID_3425; (3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; Paroxetine (TN); (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)methyl)piperidine; DSSTox_RID_77022; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S,4R)-; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S-trans)-; DSSTox_GSID_23425; CHEMBL1708; piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S,4R)-; HSDB 7175; (-)-Paroxetine; PAROXETINE HCL HEMIHYDRATE; CAS-61869-08-7; Paroxetine (USP/INN); (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; 3h-paroxetine; Paroxetine.HCl; Paroxetin HCL; Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S-trans)-; NCGC00182968-01; 8PR; NNC-20-7051; Spectrum_001752; SpecPlus_000788; Prestwick3_000851; Spectrum5_001665; SCHEMBL27799; BSPBio_000861; KBioSS_002232; BIDD:GT0673; DivK1c_006884; BPBio1_000949; GTPL4790; DTXSID3023425; BDBM22416; KBio1_001828; KBio2_002232; KBio2_004800; KBio2_007368; AHOUBRCZNHFOSL-YOEHRIQHSA-N; HMS2090H05; ZINC527386; KS-00000JK2; Tox21_113123; BDBM50331515; (-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine; AKOS015888636; Tox21_113123_1; AC-8185; DB00715; SDCCGSBI-0051908.P003; (-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine; (3S-trans)-3-[(1,3-Benzodioxol-5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine; NCGC00025355-02; NCGC00025355-03; NCGC00025355-04; NCGC00025355-05; NCGC00025355-06; NCGC00025355-07; NCGC00025355-08; NCGC00025355-09; NCGC00025355-12; CC-33477; SC-16100; SC-22977; SBI-0051908.P002; LS-114249; AB00514724; FT-0085087; C07415; D02362; AB00053704-21; AB00053704_22; AB00053704_23; Paroxetine Hydrochloride Anhydrous EP Impurity E; 869P087; C-19975; paroxetine hydrochloride (anhydrous or hemihydrate); Q408471; BRD-K37991163-003-02-7; BRD-K37991163-050-05-1; (3S,4R)-3-{[(2H-1,3-Benzodioxol-5-yl)oxy]methyl}-4-(4-fluorophenyl)piperidine; Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-,(3S,4R)-; cis-Paroxetine; Paroxetine USP Related Compound D; [(3S,4R)-4-(p-Fluorophenyl)-3-piperidyl](1,3-dioxa-5-indanyloxy)methane; Paroxetine; BRL 29060
Patulin patulin; Clavacin; Expansin; Expansine; Clavatin; Patuline; 149-29-1; Claviform; Claviformin; Clairformin; Gigantin; Leucopin; Mycoin C3; Tercinin; Mycoin; Mycoine C3; Penicidin; Mycosin; Penatin; Terinin; Mycoin C; 4-Hydroxy-4H-furo[3,2-c]pyran-2(6H)-one; Sch-351633; NSC 8120; NSC 32951; 4-Hydroxy-4H-furo(3,2-C)pyran-2(6H)-one; 4H-Furo[3,2-c]pyran-2(6H)-one, 4-hydroxy-; CCRIS 4940; (2,4-Dihydroxy-2H-pyran-3(6H)-ylidene)acetic acid, 3,4-lactone; 4,6-Dihydro-4-hydroxy-2H-furo(3,2-c)pyran-2-one; HSDB 3522; NSC8120; NSC32951; EINECS 205-735-2; 4-hydroxy-4,6-dihydrofuro[3,2-c]pyran-2-one; 4H-Furo(3,2-c)pyran-2(6H)-one, 4-hydroxy-; SCH 351633; (2,4-Dihydroxy-2H-pyran-3(6H)-ylidene)acetic acid-3,4-lactone; BRN 0149675; 4,6-dihydro-4-hydroxy-2H-furo[3,2-c]pyran-2-one; CHEMBL294018; CHEBI:74926; ZRWPUFFVAOMMNM-UHFFFAOYSA-N; 4H-Furo(3,3-c)pyran-2(6H)-one, 4-hydroxy-; Acetic acid, (2,4-dihydroxy-2H-pyran-3(6H)-ylidene)-, 3,4-lactone; Patulin, 99%; (2, 3,4-lactone; 2,4-Dihydroxy-2H-pyran-delta-3(6H),alpha-acetic acid-3,4-lactone; 2H-Pyran-delta(sup 3(6H),alpha)-acetic acid, 2,4-dihydroxy-, 3,4-lactone; 4-Hydroxy-4,6-dihydrofuro[4,5-c]pyran-2-one; 4H-Furo[3, 4-hydroxy-; 4-hydroxy-4,6-dihydro-2H-furo[3,2-c]pyran-2-one; 2,.alpha.-acetic acid, 3,4-lactone; Patulin 100 microg/mL in Acetonitrile; WLN: T56 BOV GO IU & TJ FQ; 748133-69-9; SR-05000002238; Clavicin; Clavitin; Expansion; 2H-Pyran-.delta.(sup 3(6H), 2,4-dihydroxy-, 3,4-lactone; Acetic acid,4-dihydroxy-2H-pyran-3(6H)-ylidene)-, 3,4-lactone; Gigantic acid?; MFCD00005858; Spectrum_000015; Antibiotic YS 1649; Spectrum3_000796; Spectrum4_000753; Spectrum5_001659; Standard Solution Patulin; PATULIN 13C3; Antibiotic Sch 351633; Patulin, reference material; Neuro_000008; Clairformin; Patuline; Clavatin; SCHEMBL29056; BSPBio_002532; KBioGR_001106; KBioSS_000355; 5-18-03-00005 (Beilstein Handbook Reference); DivK1c_000438; SPECTRUM1503904; MEGxm0_000442; DTXSID2021101; ACon1_002106; HMS501F20; KBio1_000438; KBio2_000355; KBio2_002923; KBio2_005491; KBio3_001752; NINDS_000438; ZX-AFC003098; HMS1923M19; Patulin, >=98.0% (HPLC); BCP29227; HY-N6779; NSC-8120; BDBM50158841; CP0142; LS-868; NSC-32951; AKOS015904103; CCG-208451; DB15586; FCH1114665; YS 1649; IDI1_000438; SMP1_000230; NCGC00095272-01; NCGC00095272-02; NCGC00095272-03; NCGC00095272-04; NCGC00095272-05; CC-33482; NCI60_041782; DB-042987; TR-006033; 4-Hydroxy-4H,6H-furo[3,2-c]pyran-2-one; CS-0083018; FT-0631849; ST50824441; 4-Hydroxy-4H-Furo(3,3-c)pyran-2(6H)-one; C16748; 4-hydroxy-2H,4H,6H-furo[3,2-c]pyran-2-one; 4-hydroxy-6-hydro-4H-furano[3,2-c]pyran-2-one; C-30428; Q414526; J-008576; SR-05000002238-2; SR-05000002238-3; 2,4-Dihydroxy-2H-pyran-alpha -acetic acid, 3, 4-lactone; 4-Hydroxy-4H-furo[3,2-c]pyran-2(6H)-one, 9CI, 8CI; 2H-Pyran-.delta.(sup 3(6H), 2,4-dihydroxy-,3,4-lactone; 2H-Pyran-alpha )-acetic acid, 2, 4-dihydroxy-,3,4-lactone; 2H-Pyran-alpha )-acetic acid, 2,4-dihydroxy-, 3,4-lactone; Patulin solution, 100 mug/mL in acetonitrile, analytical standard; Patulin solution, 100 mug/mL in chloroform, analytical standard; 2,4-Dihydroxy-2H-pyran-.delta.-3(6H),.alpha.-acetic acid, 3,4-lactone; 2H-Pyran-.delta.(3(6H),.alpha.)-acetic acid, 2,4-dihydroxy-,3,4-lactone; Patulin solution, certified reference material, 100 mug/mL in chloroform, ampule of 1 mL; 247172-18-5; 5-18-03-00005 (Beilstein Handbook Reference)
Penems Biapenem; Doripenem; Ertapenem; Faropenem; Imipenem; Meropenem; Vaborbactam; Panipenem
Penicillamine 3-Mercapto-D-valine; D-Penicillamine; penicillamine; 52-67-5; D-(-)-Penicillamine; Cuprimine; 3-Mercapto-D-valine; Depen; Cuprenil; D-Penamine; (-)-Penicillamine; Artamine; D-Mercaptovaline; (2S)-2-Amino-3-methyl-3-sulfanylbutanoic acid; Mercaptovaline; Cupripen; D-Valine, 3-mercapto-; Depamine; Kuprenil; Mercaptyl; Metalcaptase; Pendramine; Penicillamin; Perdolat; Trolovol; (S)-3,3-Dimethylcysteine; Penicilamina; Penicillaminum; Sufirtan; 3-sulfanyl-D-valine; D-beta,beta-Dimethylcysteine; D-3-Mercaptovaline; beta,beta-Dimethylcysteine; D-Penicilamine; Penicillamina [DCIT]; (S)-Penicillamin; (S)-Penicillamine; d,3-Mercaptovaline; Reduced penicillamine; Penicilamina [INN-Spanish]; Penicillaminum [INN-Latin]; Reduced D-penicillamine; beta-Thiovaline; Dimethylcysteine; (D)-PENICILLAMINE; UNII-GNN1DV99GX; 3,3-Dimethyl-D-cysteine; Valine, 3-mercapto-, D-; (S)-2-amino-3-mercapto-3-methylbutanoic acid; Distamine; 3,3-Dimethyl-D(-)-cysteine; CCRIS 2904; CHEBI:7959; HSDB 3378; EINECS 200-148-8; Penicillamine (Cuprimine); MFCD00064302; NSC 81549; GNN1DV99GX; alpha-Amino-beta-methyl-beta-mercaptobutyric acid; (2S)-2-amino-3-methyl-3-sulfanyl-butanoic acid; CHEMBL1430; NCGC00024359-04; Penicillamina; Copper penicillaminate; Sufortan; Cuprimine (TN); D-beta-Mercaptovaline; Depen (TN); SR-01000000262; Penicillamine [USAN:INN:BAN:JAN]; Distamine (*Hydrochloride*); D(-)-Penicillamine, 99%, specified according to Ph.Eur. and USP; Penicillamine (JAN/USP/INN); Metalcaptase (*Hydrochloride*); Penicillamine,(S); NSC81549; NSC-81549; Spectrum_000283; Penicillamine [USAN:USP:INN:BAN:JAN]; Spectrum2_001029; Spectrum3_000541; Spectrum4_000470; Spectrum5_001196; Epitope ID:113237; P-1280; SCHEMBL4343; DSSTox_CID_17069; DSSTox_RID_79300; D-(-)-2-Amino-3-mercapto-3-methylbutanoic acid; DSSTox_GSID_37069; BSPBio_002181; KBioGR_000920; KBioSS_000763; cid_92173; DivK1c_000314; SPBio_001217; D-Penicillamine, 98-101%; GTPL7264; DTXSID6037069; BDBM39346; CTK1G9784; KBio1_000314; KBio2_000763; KBio2_003331; KBio2_005899; KBio3_001681; NINDS_000314; VVNCNSJFMMFHPL-VKHMYHEASA-N; ZINC114127; BCP17247; HY-B0300; KS-000001ON; STR02534; Tox21_110899; ANW-31517; BDBM50217941; s1853; AKOS006237201; ZINC100509167; AM83710; CS-2334; DB00859; MCULE-5986342172; RTR-032192; CAS-52-67-5; IDI1_000314; SMP1_000042; NCGC00018283-01; NCGC00024359-05; NCGC00024359-06; CPD000653530; SAM002548964; AB0010552; AB2000333; LS-161321; TR-032192; FT-0624341; P0147; EN300-52608; C07418; D00496; K-9599; (2S)-2-amino-3-mercapto-3-methyl-butyric acid; (2S)-2-amino-3-mercapto-3-methylbutanoic acid; 24217-EP2272832A1; 24217-EP2281815A1; 24217-EP2301933A1; 24217-EP2305640A2; 24217-EP2311827A1; 24217-EP2311842A2; 24217-EP2314590A1; 24217-EP2371811A2; 24217-EP2380872A1; (2S)-2-azanyl-3-methyl-3-sulfanyl-butanoic acid; 064P302; Q421239; SR-01000000262-3; SR-01000000262-4; UNII-2XOP7Y1H98 component VVNCNSJFMMFHPL-VKHMYHEASA-N; (2S)-2-amino-3-mercapto-3-methyl-butyric acid; hydrochloride; (2S)-2-amino-3-mercapto-3-methylbutanoic acid; hydrochloride; (2S)-2-amino-3-methyl-3-sulfanylbutanoic acid; hydrochloride; (2S)-2-azanyl-3-methyl-3-sulfanyl-butanoic acid; hydrochloride; Depen; Distamine; D-Mercaptovaline; D-Penamine; Kuprenil; Cuprimine; Penicillamine, European Pharmacopoeia (EP) Reference Standard; (2S)-2-amino-3-methyl-3-sulfanylbutanoic acid3-sulfanyl-D-valine; Penicillamine, United States Pharmacopeia (USP) Reference Standard; 771431-20-0; Penicillamine; alpha-Amino-beta-methyl-beta-mercaptobutyric acid
Penicillin K (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[(1-oxooctyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Penicillin K; 3,3-Dimethyl-6-octanamido-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
Penicillin g (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Penicillin G; 4-27-00-05861 (Beilstein Handbook Reference)
Penicillin v (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Penicillin V; 4-27-00-05884 (Beilstein Handbook Reference)
Penicillins (amidinopenicillin) Mecillinam; Pivemeillinam
Penicillins (aminopenicillin with beta-lactamase inhibitors) Amoxicillin-Clavulanic Acid; Ampicillin-Sulbactam
Penicillins (aminopenicillin) Amoxicillin; Ampicillin; Azidocillin; Bacampicillin; Epicillin; Hetacillin; Metampicillin; Pivampicillin; Sultamicillin; Talampicillin; Temocillin
Penicillins (antipseudomonal) Azlocillin; Carbenicillin; Carindacillin; Mezlocillin; Piperacillin; Piperacillin-Tazobactam; Sulbenicillin; Ticarcillin; Ticarcillin-Clavulanic-Acid
Penicillins (antistaphylococcal) Cloxacillin; Dicloxacillin; Flucloxacillin; Meticillin; Methicillin; Oxacillin; Nafcillin
Penicillins (narrow spectrum) Benzathinebenzylpenicillin; Benethaminebenzylpenicillin; Benzylpenicillin; Penicillin G; Clometocillin; Penamecillin; Penethamate Hydriodide; Pheneticillin; Phenoxymethylpenicillin; Penicillin V; Procaine Benzylpenicillin; Propicillin
Pentabromophenol PENTABROMOPHENOL; 608-71-9; Phenol, pentabromo-; 2,3,4,5,6-Pentabromophenol; Flammex 5BP; pentabromphenol; Pentabromfenol; Pentabromfenol [Czech]; UNII-V89A88NMMX; CCRIS 4853; HSDB 5500; NSC 5717; EINECS 210-167-3; BRN 1876757; V89A88NMMX; AI3-01561; SVHOVVJFOWGYJO-UHFFFAOYSA-N; Phenol, 2,3,4,5,6-pentabromo-; C6HBr5O; Phenol,2,3,4,5,6-pentabromo-; PubChem13350; 1e4h; Pentabromophenol, 96%; ACMC-1AWHG; DSSTox_CID_2079; DSSTox_RID_76480; DSSTox_GSID_22079; 3-06-00-00766 (Beilstein Handbook Reference); MLS002152927; PENTABROMOHYDROXYBENZENE; SCHEMBL268325; CHEMBL1235157; DTXSID9022079; CTK5B2381; NSC5717; WLN: QR BE CE DE EE FE; 2,3,4,5,6-Pentabromophenol #; NSC-5717; ZINC1687157; Tox21_200339; 2,3,4,5,6-pentakis(bromanyl)phenol; AKOS003672224; AS04485; DB03167; FCH1321427; LS-1448; NCGC00090884-01; NCGC00090884-02; NCGC00257893-01; AS-13066; BC003735; CAS-608-71-9; CC-33524; PBR; SMR001224527; TC-165569; FT-0739390; A832934; C-34165; Q27094104; 3-06-00-00766 (Beilstein Handbook Reference)
Pentanal PENTANAL; Valeraldehyde; n-Pentanal; 110-62-3; n-Valeraldehyde; Valeric aldehyde; Valeral; Valeryl aldehyde; Amylaldehyde; Butyl formal; Amyl aldehyde; Valeric acid aldehyde; Valerianic aldehyde; Valerylaldehyde; n-Valeric aldehyde; Pentyl aldehyde; 1-pentanal; FEMA Number 3098; n-Valeraldehyde (natural); pentan-1-al; MFCD00007026; NSC 35404; FEMA No. 3098; CCRIS 3220; HSDB 851; Valeraldehyde, 97%; UNII-B975S3014W; n-C4H9CHO; EINECS 203-784-4; UN2058; BRN 1616304; CHEMBL18602; AI3-16105; CHEBI:84069; HGBOYTHUEUWSSQ-UHFFFAOYSA-N; B975S3014W; Valeraldehyde [UN2058] [Flammable liquid]; Pentanaldehyde; Aldehydes, C5; pentylaldehyde; n-BuCHO; N-Valeraldehyde, 8CI; ACMC-1CCBN; pentanal (valeraldehyde); DSSTox_CID_1653; EC 203-784-4; WLN: VH4; DSSTox_RID_76265; DSSTox_GSID_21653; 4-01-00-03268 (Beilstein Handbook Reference); KSC175C8H; Valeraldehyde, >=97%, FG; DTXSID7021653; CTK0H5183; FEMA 3098; KS-00000UFO; Valeraldehyde, analytical standard; NSC35404; STR03921; ZINC1667603; Tox21_300061; ANW-16174; BBL027632; BDBM50028837; CV0015; LMFA06000251; LS-511; NSC-35404; STL194259; AKOS000119170; DB01919; MCULE-4736782822; RTX-012524; TRA0020924; UN 2058; NCGC00091722-01; NCGC00091722-02; NCGC00253979-01; CAS-110-62-3; I852; PNO; SC-22704; Valeraldehyde [UN2058] [Flammable liquid]; 6418-EP2374783A1; 6418-EP2377841A1; 61324-EP2277874A1; 61324-EP2308848A1; Q420652; J-002454; F2190-0583; InChI=1/C5H10O/c1-2-3-4-5-6/h5H,2-4H2,1H; 4-01-00-03268 (Beilstein Handbook Reference)
Pentazocine 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; Talwin; Liticon; Fortalgesic; Fortral; Pentazocin; NSC-107430; Fortalin; Pentagin; Sosegon; Sosigon; CHEMBL100116; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; Pentazocaine; 55643-30-6; II-C-2; 359-83-1; 2-(3,3-Dimethylallyl)cyclazocine; NIH 7958; WIN 20228; KF-1820; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2.alpha.,6.alpha.,11R*)-; (-)-PENTAZOCINE; PENTAZOCINE (+); PENTAZOCINE (-); 2-Dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan; Soseton; Talwan; Pentazocine civ; 2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan; 2-(3,3-Dimethylallyl)-2',2'-hydroxy-5,9-dimethyl-6,7-benzomorphan; NSC107430; WIN-20228; 3-(3-Methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol; (2R*,6R*,11R*)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-; EINECS 259-735-2; Algopent (free base); (.+/-.)-Pentazocine; SCHEMBL2493; VOKSWYLNZZRQPF-UHFFFAOYSA-N; (2a,6a,11R*)-(+/-)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; 39188-58-4; 6,11-Dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol; BDBM50032403; PDSP1_000673; PDSP2_000663; LS-89500; DB-048905; L001017; dl-2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan; Pentazocine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; (Pentazocine) 6,11-Dimethyl-3-(3-methyl-but-2-enyl)-1,2 ,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol; (Pentazocine) 6,11-Dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol; (pentazocine)2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-pentanedioic acid; 1,13-dimethyl-10-(3-methyl-2-butenyl)-(1R,9R,13R)-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol(Pentazocine); 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2R,6R,11R)-rel-; 2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(15S)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol(Pentazocine); 6,11-Dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol (pentazocine); 6,11-Dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol; lactate; pentazocine; L-pentazocine; Pentazocinum; Pentazocin; Fortral; Fortalgesic; Fortalin; Pentagin; Sosigon; dl-Pentazocine; (-)-PENTAZOCINE; UNII-768DQ5A5AI; Pentazocaine; Sosegon; CHEMBL560; Pentazocina [DCIT]; 359-83-1; 768DQ5A5AI; CHEBI:7982; 7488-49-5; Pentazocinum [INN-Latin]; II-C-2; Pentazocina; 2-(3,3-Dimethylallyl)cyclazocine; NIH 7958; WIN 20228; KF-1820; (2R,6R,11R)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol; HSDB 3150; Levopentazocine; EINECS 206-634-6; 2-Dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan; NSC 107430; Pentazocine, L-; Fortral (TN); 2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan; PENTAZOCINE (+); PENTAZOCINE (-); 2-(3,3-Dimethylallyl)-2',2'-hydroxy-5,9-dimethyl-6,7-benzomorphan; cis-(-)-Pentazocine; Pentazocine, (-)-; (-)-alpha-Pentazocine; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; 3-(3-Methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol; (2R*,6R*,11R*)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; Pentazocine 2R,6R,11R-form; WIN-20228; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2alpha,6alpha,11R*)-; (+-)-Pentazocine; Pentazocine 2R,6R,11R-form [MI]; Pentazocine,(+/-); Pentazocine [USAN:USP:INN:BAN:JAN]; cis-(+-)-Pentazocine; SCHEMBL2492; ZINC596; GTPL1606; Pentazocine (JP17/USP/INN); DTXSID7023433; (2a,6a,11R*)-(+/-)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; (2R,6R,11R)-6,11-Dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol; (6R,11S)-6,11-Dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol; 6,11-Dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol; EINECS 244-593-6; BDBM50001028; API0003785; DB00652; WIN 20,228; (2alpha,6alpha,11R*)-(1)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-buten-1-yl)-, (2R,6R,11R)-; CC-33571; FT-0673607; C07421; D00498; C-17980; Q415793; UNII-RP4A60D26L component VOKSWYLNZZRQPF-GDIGMMSISA-N; (1R,9R,13R)-1,13-dimethyl-10-(3-methylbut-2-en-1-yl)-10-azatricyclo[7.3.1.0^{2,7}]trideca-2,4,6-trien-4-ol; 6,11-Dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol(Pentazocine); rel-(2R,6R,11R)-6,11-Dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol; Rel-Pentazocine; CHEMBL397705; (-)-PENTAZOCINE; Fortalgesic; Pentazocin; Fortalin; Fortral; Pentagin; Sosegon; Sosigon; C19H27NO; DEA No. 9709; Pentazocina [DCIT]; Pentazocinum [INN-Latin]; II-C-2; HSDB 3150; 2-(3,3-Dimethylallyl)cyclazocine; Lexir; NIH 7958; EINECS 206-634-6; NSC107430; WIN 20228; KF-1820; NSC 107430; 2-Dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan; (?)-9-epi-Pentazocine; SCHEMBL135685; 2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan; 2-(3,3-Dimethylallyl)-2',2'-hydroxy-5,9-dimethyl-6,7-benzomorphan; (2R*,6R*,11R*)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2alpha,6alpha,11R*)-; 3-(3-Methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol; 359-83-1; 39188-58-4; Pentazocine [USAN:INN:BAN:JAN]; BDBM50001033; BDBM50407300; PDSP2_001111; LS-90597; Pentazocine, Pentazocin, Sosegon, WIN 20228; Pentazocine; 2-(3,3-Dimethylallyl)cyclazocine
Pentobarbital 5-Ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; pentobarbital; Pentobarbitone; Nembutal; Mebubarbital; Ethaminal; Mebumal; Pentobarbituric acid; Neodorm; Dorsital; Nebralin; Rivadorm; Pentobarbiturate; 76-74-4; Pentabarbitone; Neodorm (new); Pentabarbital; Pentobarbitalum; Aethaminalum; 5-Ethyl-5-(sec-pentyl)barbituric acid; 5-Ethyl-5-(1-methylbutyl)barbituric acid; Nembutal (VAN); Neodorm (VAN); Pentobarbital (VAN); Pentobarbitone (VAN); Pentobarbitale [DCIT]; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)-; 5-Ethyl-5-(1-methylbutyl)malonylurea; 5-Ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; Pentobarbitalum [INN-Latin]; NSC 28708; Pentobarbital calcium; Barbituric acid, 5-ethyl-5-(1-methylbutyl)-; Diabutal; Ethyl-propylmethylcarbinylbarbituric acid; CCRIS 7089; HSDB 3151; EINECS 200-983-8; 5-ethyl-5-(pentan-2-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; CHEMBL448; BRN 0087067; 5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione; Barbituric acid, 5-ethyl-5-(2-pentyl)-; CHEBI:7983; WEXRUCMBJFQVBZ-UHFFFAOYSA-N; (+-)-5-Ethyl-5-(1-methylbutyl)barbituric acid; NSC-28708; NCGC00096074-01; Pentobarbitale; Etaminal; 5-Ethyl-5-(1-methyl-butyl)-pyrimidine-2,4,6-trione; 5-ethyl-5-(pentan-2-yl)-1,3-diazinane-2,4,6-trione; Phetobarbitone; 5-ethyl-2-hydroxy-5-(1-methylbutyl)pyrimidine-4,6(1H,5H)-dione; Pentobarbital [USP:INN]; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)-, (+-)-; Nembutal (TN); Pentobarbital, Monosodium Salt; Pentobarbital (USP/INN); Pentobarbital [USP:INN:BAN]; SR-01000317092; Pentobarbital cii; (RS)-pentobarbital; Pentobarbital suppository dosage form; Continal (Salt/Mix); (plusmn)-pentobarbital; Sedalixir (Salt/Mix); Spectrum_001783; 57-33-0; Spectrum2_001991; Spectrum3_001783; Spectrum4_000574; Spectrum5_001705; DSSTox_CID_3435; EC 200-983-8; (.+/-.))-Pentobarbital; DSSTox_RID_77026; DSSTox_GSID_23435; Oprea1_143902; Oprea1_775730; SCHEMBL24966; BSPBio_003305; KBioGR_001008; KBioSS_002267; 5-24-09-00168 (Beilstein Handbook Reference); DivK1c_000992; SPECTRUM1900006; SPBio_002201; GTPL5480; DTXSID7023435; SCHEMBL11114711; component of Emesert (Salt/Mix); component of Synirin (Salt/Mix); HMS503G05; KBio1_000992; KBio2_002266; KBio2_004834; KBio2_007402; KBio3_002807; NINDS_000992; HMS2094E21; HMS3713B10; Pharmakon1600-01900006; NSC28708; Tox21_111555; BBL028072; BDBM50055935; CCG-39476; NSC760434; STL367899; Pentobarbital 0.1 mg/ml in Methanol; Pentobarbital 1.0 mg/ml in Methanol; AKOS000277861; WLN: T6VMVMV FHJ FY3&1 F2; API0004783; CCG-220564; DB00312; NSC-760434; CAS-76-74-4; IDI1_000992; NCGC00096074-02; CC-33572; LS-24385; SBI-0052713.P002; DB-056119; C07422; D00499; 057P561; C-12883; Nembutal|||5-Ethyl-5-(sec-pentyl)barbituric acid; Q409632; SR-05000001789; SR-01000317092-2; SR-05000001789-1; BRD-A44448661-001-01-4; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-sec-pentyl-; 2,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)-; 5-Ethyl-5-(1-methylbutyl)-2,6(1H,3H,5H)-pyrimidinetrione; Pentobarbital, European Pharmacopoeia (EP) Reference Standard; Pentobarbital, United States Pharmacopeia (USP) Reference Standard; Pentobarbital solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; 30849-50-4; Pentobarbital; 5-24-09-00168 (Beilstein Handbook Reference)
Perchlorate Perchlorate; PERCHLORATE ION; 14797-73-0; UNII-VLA4NZX2P4; VLA4NZX2P4; Perchlorate ions; Perchlorate(1-); ClO4; Perchlorate ion(1-); ClO4-; Perchlorate ion (ClO41-); Perchlorat; Chlorat(VII); tetraoxochlorate(1-); tetraoxochlorate(VII); OClO3; tetraoxidochlorate(1-); Perchlorate (8CI,9CI); ClO4(-); DTXSID6024252; BDBM36131; CHEBI:49706; CTK0H7695; VLTRZXGMWDSKGL-UHFFFAOYSA-M; [ClO4](-); DB03138; Perchlorate (ClO4) and Perchlorate Salts; LS-193718; Q407189; Perchlorate ion(1-)
Perflubron 1-Bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane; Perflubron; 1-Bromoperfluorooctane; 423-55-2; Perfluorooctyl bromide; 1-Bromoheptadecafluorooctane; Perfluoro-n-octyl Bromide; Oxygent; Imagent GI; Perfluorooctylbromide; LiquiVent; Perfluoroctyl bromide; PFOB; Long's compound; IMAGENT; C8BrF17; Bromoperfluoroctane; UNII-Q1D0Q7R4D9; 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane; Heptadecafluoro-n-octyl Bromide; WTWWXOGTJWMJHI-UHFFFAOYSA-N; EINECS 207-028-4; Q1D0Q7R4D9; CHEBI:38803; Octane, 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro-; OCTANE, 1-BROMOHEPTADECAFLUORO-; NCGC00166217-01; DSSTox_CID_26560; DSSTox_RID_81719; DSSTox_GSID_46560; Perfluorooctyl bromide, 99%; Imagent BP; perflubron emulsion; perfluoroctylbromide; CAS-423-55-2; Perflubron [USAN:INN]; Perflubron [USAN:USP:INN]; Imagent (TN); perfluoro-octylbromide; LA11063; LA 11063; Perflubron (USP/INN); ACMC-1AP0C; L 1913; bromure de n-perfluorooctyle; SCHEMBL33826; 1-bromo-heptadecafluoro-octane; CHEMBL1200866; DTXSID5046560; CF3-(CF2)6-CF2-Br; CTK3J2391; 1-Bromoheptadecafluorooctane, 99%; HY-B1724; KS-000001AW; ZINC8214650; ZX-AP003882; Tox21_112353; 3113AE; ANW-29799; MFCD00042082; AKOS015833872; Tox21_112353_1; DB05791; DIMYRISTOYL LECITHIN; PERFLEXANE; FS-4333; RTR-033009; TRA0002114; NCGC00166217-02; CC-04278; LS-97848; SC-78379; AB1011042; DB-050901; TR-033009; CS-0013729; FT-0607546; D05439; K-8801; C-22932; SR-01000944517; Q2190150; SR-01000944517-1; Perflubron, United States Pharmacopeia (USP) Reference Standard; Perflubron; 1-Bromoperfluorooctane
Phenacetin N-(4-Ethoxyphenyl)acetamide; phenacetin; 62-44-2; Acetophenetidin; N-(4-Ethoxyphenyl)acetamide; Acetphenetidin; Acetophenetidine; Acetophenetin; Phenacetine; p-Acetophenetidide; Contradouleur; 4'-Ethoxyacetanilide; Achrocidin; Codempiral; Commotional; Contradol; Phenazetin; Acetamide, N-(4-ethoxyphenyl)-; 4-Ethoxyacetanilide; p-Acetophenetidine; Fenacetina; Fenidina; Pertonal; Phenacet; Phenacetinum; Phenacitin; Phenedina; Phenidin; Pyraphen; Fenina; Kalmin; p-Ethoxyacetanilide; Phenin; p-Acetophenetide; p-Acetphenetidin; Phenazetina; Tetracydin; Clistanol; Coriforte; Daprisal; Dasikon; Dolostop; Edrisal; Empiral; Emprazil; Epragen; Fortacyl; Gelonida; Gewodin; Helvagit; Hocophen; Melabon; Melaforte; Pamprin; Paramette; Paratodol; Phenodyne; Pyrroxate; Quadronal; Salgydal; Sanalgine; Seranex; Sinedal; Sinubid; Sinutab; Stellacyl; Synalogos; Treupel; Veganine; Anapac; Fenia; Malex; Tacol; Viden; Xaril; Acetylphenetidin; para-Phenacetin; Bromo seltzer; Kafa; Phenaphen plus; Robaxisal-ph; Aceto-4-phenetidine; Citra-fort; Super Anahist; Dasin ch; Emprazil-C; Acet-p-phenalide; Coryban-D; Paracetophenetidin; Hjorton'S powder; Acet-p-phenetidin; Thephorin A-C; N-Acetyl-p-phenetidine; Buff-A-Comp; Para-acetphenetidin; 1-Acetamido-4-ethoxybenzene; Fiorinal; Sinutabs; Saridon; Aceto-para-phenalide; para-Acetophenetidide; Darvon compound; Acetanilide, 4'-ethoxy-; Synalgos-dc; p-Phenetidine, N-acetyl-; Aceto-para-phenetidide; Fenacetin [Czech]; Rcra waste number U187; para-Acetophenetidine; Fenacetin; para-Ethoxyacetanilide; Fenacetina [INN-Spanish]; N-para-Ethoxyphenylacetamide; CCRIS 496; HSDB 3152; N-Acetyl-4-ethoxyaniline; N-Acetyl-para-phenetidine; Phenacetine [INN-French]; Phenacetinum [INN-Latin]; UNII-ER0CTH01H9; p-Ethoxyanilid kyseliny octove; p-Ethoxyanilid kyseliny octove [Czech]; BRN 1869238; Acetic acid amide, N-(4-ethoxyphenyl)-; 1-Acetyl-p-phenetidin; AI3-00783; Acetamide, N-(4-ethoxyphenol)-; NSC 7651; 4-(Acetylamino)phenetole; EINECS 200-533-0; RCRA waste no. U187; ER0CTH01H9; N-(4-ethoxyphenyl)ethanamide; N-(4-ethoxyphenyl)-acetamide; CHEBI:8050; N-[4-(ethyloxy)phenyl]acetamide; CPJSUEIXXCENMM-UHFFFAOYSA-N; MFCD00009094; CAS-62-44-2; NCGC00016281-06; DSSTox_CID_1116; DSSTox_RID_75948; DSSTox_GSID_21116; Phenacetin [Analgesic mixtures containing phenacetin]; SMR000752916; Phenacetin [INN:JAN]; SR-01000787183; Acetophenidin; Terracydin; Phenacetin [USP:INN:JAN]; paracetophentidin; Acetylphenetidine; Zactirin compound; p-Acetophenetitide; acet-p-phenal ide; 4-Acetophenetidide; Prestwick_862; Phenacetin, 97%; 4-Ethoxy-acetanilid; N-acetylphenetylamine; 4-Ethoxy-acetanilide; ASA COMPOUND; Butigetic (Salt/Mix); Spectrum_000782; Acetanilide, p-ethoxy-; Phenacetin (JAN/INN); N-Acetyl-p-ethoxyaniline; Prestwick0_000533; Prestwick1_000533; Prestwick2_000533; Prestwick3_000533; Spectrum2_001940; Spectrum3_001404; Spectrum4_000515; Spectrum5_001902; p-Acetophenetidide (8CI); N-Acetyl-4-ethoxyani line; WLN: 2OR DMV1; SCHEMBL23280; 4'-Ethoxyacetanilide, 97%; BSPBio_000545; BSPBio_003048; KBioGR_001089; KBioSS_001262; ZINC602; MLS001304971; MLS002153862; MLS002303055; 4-Ethoxy-1-acetylaminobenzene; ARONIS25011; CHEMBL16073; DivK1c_000580; P-A-C Compound (Salt/Mix); SPECTRUM1500642; SPBio_001979; SPBio_002466; BPBio1_000601; GTPL7402; DTXSID1021116; SCHEMBL20476396; HMS501M22; KBio1_000580; KBio2_001262; KBio2_003830; KBio2_006398; KBio3_002268; NSC7651; NINDS_000580; HMS1569L07; HMS1921M21; HMS2092E14; HMS2096L07; HMS2234P11; HMS3373I02; HMS3651N07; HMS3713L07; Pharmakon1600-01500642; BCP09084; HY-B0476; KS-00000W7P; KS-000046XI; NSC-7651; Phenacetin, >=98.0% (HPLC); Tox21_110347; Tox21_201926; Tox21_302895; BBL004038; BDBM50420191; CCG-39439; LS-269; NSC757401; STK011463; AKOS000370201; Phenacetin 1.0 mg/ml in Acetonitrile; Tox21_110347_1; ACN-048769; CS-2590; DB03783; MCULE-2069106916; NSC-757401; IDI1_000580; Acetamide, N-(4-ethoxyphenyl)- (9CI); NCGC00016281-01; NCGC00016281-02; NCGC00016281-03; NCGC00016281-04; NCGC00016281-05; NCGC00016281-07; NCGC00016281-08; NCGC00016281-11; NCGC00091376-01; NCGC00091376-02; NCGC00091376-03; NCGC00091376-04; NCGC00091376-05; NCGC00256345-01; NCGC00259475-01; AC-28909; AK174284; S361; SC-18380; SBI-0051571.P002; AB1009489; DB-054164; Phenacetin, Vetec(TM) reagent grade, 98%; AB00052135; FT-0631277; P1669; S2577; ST45053771; SW196989-3; T8098; A11906; BIM-0051571.0001; C07591; D00569; AB00052135_10; AB00052135_11; A833774; AE-848/04969036; Q419175; SR-01000787183-2; SR-01000787183-3; BRD-K38323065-001-05-8; BRD-K38323065-001-09-0; Phenacetin, United States Pharmacopeia (USP) Reference Standard; Phenacetin Melting Point Standard, United States Pharmacopeia (USP) Reference Standard; 1-Acetyl-p-phenetidin; 4 inverted exclamation marka-Ethoxyacetanilide; N-(4-Ethoxyphenyl)acetamide; p-Acetophenetidide; Acetophenetidin; InChI=1/C10H13NO2/c1-3-13-10-6-4-9(5-7-10)11-8(2)12/h4-7H,3H2,1-2H3,(H,11,12; N4E; Phenacetin melting point standard, Pharmaceutical Secondary Standard; Certified Reference Material; Phenacetin solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material; Acetamide, N-(4-ethoxyphenyl)-; 4-13-00-01092 (Beilstein Handbook Reference)
Phenethylamine Benzeneethanamine; Phenethylamine; 2-phenylethylamine; 2-Phenylethanamine; 64-04-0; Benzeneethanamine; phenylethylamine; 2-Phenethylamine; beta-phenylethylamine; beta-Phenethylamine; 1-Amino-2-phenylethane; 2-Phenylethan-1-Amine; beta-Aminoethylbenzene; (2-Aminoethyl)benzene; 1-Phenyl-2-aminoethane; 2-Amino-1-phenylethane; Ethanamine, 2-phenyl-; Ethylamine, 2-phenyl-; 1-Phenyl-2-amino-athan; 2-Fenylethylamin; 2-Amino-fenylethan; 2-Fenylethylamin [Czech]; PHENETHYLAMINE, BETA; 2-Amino-fenylethan [Czech]; beta-Phenylaethylamin [German]; 2-Aminoethylbenzene; beta-Phenylaethylamin; 1-Phenyl-2-amino-athan [German]; .beta.-Phenethylamine; .beta.-Phenylethylamine; phenethyl amine; phenethyl-amine; .beta.-Aminoethylbenzene; b-phenylethylamine; 1tnj; 1utm; 1uto; UNII-327C7L2BXQ; NSC 10811; FEMA No. 3220; PHEA; C8H11N; Phenethylamine, 99%; HSDB 3526; .beta.-Phenylaethylamin; .omega.-Phenylethylamine; EINECS 200-574-4; MFCD00008184; 3-AMINOETHYLBENZENE; CHEMBL610; BRN 0507488; AI3-03117; 327C7L2BXQ; CHEBI:18397; BHHGXPLMPWCGHP-UHFFFAOYSA-N; PHENETHYLAMINE, HYDROCHLORIDE; beta-phenylaethylamin (german); 1-Phenyl-2-amino-athan (GERMAN); .beta.-Phenylathylaminhydrochlorid; SMR000471837; .beta.-Phenethylamine hydrochloride; Polystyrene A-NH2; .beta.-Phenylethylamine hydrochloride; (2-Aminoethyl)polystyrene; phenethylamin; phenethylarnine; b-phenethylamine; N-phenethylamine; Phenylethyl amine; b-phenylaethylamin; benzene-ethanamine; 2-penylethylamine; b-aminoethylbenzene; beta Phenethylamine; 2-phenylethaneamine; 2-phenylethariamine; 2-phenyl-ethylamine; 2-phenyl-Ethanamine; 2-Phenylethyl amine; N-Benzylmethyl-amine; 14C-phenylethylamine; omega-Phenylethylamine; (2-phenylethyl)amine; 2-(phenyl)ethylamine; 2-Phenylethanamine #; 2-(aminoethyl)benzene; PubChem21080; Phenethylamine, .beta.; 2-Phenethylamine, liquid; Phenethylamine, >=99%; ACMC-1ATT1; SCHEMBL968; bmse000377; EC 200-574-4; b-phenylaethylamin (german); WLN: Z2R; DL-BENZEDRINE SULFATE; AURORA KA-7805; Dextroamphetamine sulfate salt; KSC353A6F; MLS001066395; MLS001075768; SCHEMBL330324; GTPL2144; PARAGOS 510015; RARECHEM AL BW 0047; DTXSID5058773; BDBM10758; CTK2F3062; FEMA 3220; Dextroamphetamine hemisulfate salt; OTAVA-BB 1038619; HMS2267J14; LABOTEST-BB LTBB000487; ACT01135; EBD27214; KS-000002OD; NSC10811; STR01455; ZINC6579654; ANW-34793; LABOTEST-BB LT03331710; NSC-10811; s5347; SBB058801; STL264196; 2-Phenethylamine, analytical standard; 2-phenylethanamine (ACD/Name 4.0); 2-phenylethylamine (ACD/Name 4.0); AKOS000119084; AS00484; CS-W011199; DB04325; HY-W010483; LS-3025; LS10634; MCULE-5305816256; RTR-000856; NCGC00163366-01; AK-44044; BR-44044; SC-18356; (+)-alpha-Methylphenethylamine sulfate salt; DB-002852; TR-000856; TX-016680; 843-EP2272972A1; 843-EP2272973A1; 843-EP2277872A1; 843-EP2281818A1; 843-EP2284157A1; 843-EP2284174A1; 843-EP2292619A1; 843-EP2295439A1; 843-EP2305260A1; 843-EP2308510A1; 843-EP2308562A2; 843-EP2371811A2; FT-0613300; P0085; ST24032521; ST45255355; AZ0001-0092; (+)-alpha-Methylphenethylamine hemisulfate salt; C05332; 12463-EP2280001A1; 12463-EP2314571A2; 12463-EP2316826A1; 21691-EP2284174A1; 21691-EP2314571A2; 79541-EP2305695A2; 79541-EP2305696A2; 79541-EP2305697A2; 79541-EP2305698A2; 2-Phenylethylamine 100 microg/mL in Acetonitrile; Q407411; (+)-A-METHYLPHENETHYLAMINE HEMISULFATE SALT; Q-201553; (+/-)-ALPHA-METHYLPHENETHYLAMINE SULFATE SALT; Phenethylamine, purified by redistillation, >=99.5%; 60BC7032-7CEC-4B97-B365-EA6E475E6E3C; F2190-0396; Polystyrene A-NH2, extent of labeling: 0.8-1.2 mmol/g loading; InChI=1/C8H11N/c9-7-6-8-4-2-1-3-5-8/h1-5H,6-7,9H; Phenethylamine; 4-12-00-02453 (Beilstein Handbook Reference)
Phenmetrazine 3-Methyl-2-phenylmorpholine; phenmetrazine; 3-Methyl-2-phenylmorpholine; Oxazimedrine; Phenmetrazin; 134-49-6; Fenmetrazin; 2-Phenyl-3-methylmorpholine; Defenmetrazin; Psychamine A 66; Dexphenmetrazine; Morpholine, 3-methyl-2-phenyl-; Probese-P; Phenmetrazinum; Fenmetrazina [INN-Spanish]; Phenmetrazinum [INN-Latin]; Phenmetrazine [INN:BAN]; 3-Methyl-2-phenyltetrahydro-2H-1,4-oxazine; A 66; 2-Fenyl-3-methylmorfolin [Czech]; HSDB 3156; dl-2-Phenyl-3-methyltetrahydro-1,4-oxazine; EINECS 205-143-4; BRN 0140490; 2-phenyl-3-methyl-morpholine; 3-methyl-2-phenyl-morpholine; CHEBI:8067; Fenmetrazina; DEA No. 1631; Phenmetraline; W-205439; 2-Fenyl-3-methylmorfolin; NCGC00164535-01; NCGC00164535-02; SCHEMBL33984; CHEMBL1201208; DTXSID5023455; CTK6C4480; OOBHFESNSZDWIU-UHFFFAOYSA-N; ZX-AN023362; MFCD00864487; SBB072145; AKOS003662804; AB07481; API0004786; DB00830; FCH3226364; MCULE-3684334876; AC-16023; BBV-76025408; LS-93169; ST081100; FT-0699580; Y7443; C07432; Q3329406; Dexphenmetrazine; A 66
Phenolphthalein 3,3-Bis(4-hydroxyphenyl)-1(3H)-isobenzofuranone; phenolphthalein; 77-09-8; Phthalimetten; Euchessina; Phthalin; Espotabs; Phenolax; Purgophen; Koprol; Laxogen; Trilax; Purga; Lilo; Spulmako-lax; Chocolax; Feen-A-Mint Gum; Purgen; 3,3-Bis(4-hydroxyphenyl)phthalide; Correctol; Alophen; Doxidan; Medilax; Colax; Laxin; FemiLax; Dihydroxyphthalophenone; Phillips Gelcaps; 3,3-Bis(4-hydroxyphenyl)-1(3H)-isobenzofuranone; Lax-Pills; 1(3H)-Isobenzofuranone, 3,3-bis(4-hydroxyphenyl)-; Evac-Q-Kwik; Evac-Q-Tabs; Evac-Q-Kit; Evac-U-Gen; Fenolftalein; Phenolphtaleine; Phenophthalein; Agoral; Fenolftalein [Czech]; 3,3-Bis(p-hydroxyphenyl)phthalide; 3,3-Bis(4-hydroxyphenyl)isobenzofuran-1(3H)-one; NCI-C55798; Feen-A-Mint Laxative Mints; Fenolftaleina [INN-Spanish]; Phenolphtaleine [INN-French]; 3,3-Bis(4-hydroxyphenyl)-2-benzofuran-1(3H)-one; Phenolphthaleinum [INN-Latin]; alpha-Di(p-hydroxyphenyl)phthalide; UNII-6QK969R2IF; NSC 10464; component of Agoral; 3,3-bis(4-hydroxyphenyl)-1,3-dihydro-2-benzofuran-1-one; Phthalide 3,3,-bis(p-hydroxyphenyl)-; CCRIS 6266; HSDB 4161; 3,3-bis(4-hydroxyphenyl)-2-benzofuran-1-one; EINECS 201-004-7; MFCD00005913; BRN 0284423; Phenolphthalein, ACS reagent; CHEMBL63857; AI3-09081; MLS000069592; 6QK969R2IF; DTXSID0021125; CHEBI:34914; KJFMBFZCATUALV-UHFFFAOYSA-N; component of Correctol; NCGC00018200-07; SMR000059015; DSSTox_CID_1125; alpha-(p-Hydroxyphenyl)-alpha-(4-oxo-2,5-cyclohexadien-1-ylidene)-o-toluic acid; DSSTox_RID_75956; DSSTox_GSID_21125; Evac-V-Lax; 3,3-bis(4-hydroxyphenyl)-3-hydroisobenzofuran-1-one; component of Feen-A-Mint Pills; Fenolftaleina; Laxettes; Phenolphthaleinum; Phthalide 3,-bis(p-hydroxyphenyl)-; Feen-a-mint; CAS-77-09-8; Phenolphthalein Solution, Alcoholic 1.0%; WLN: T56 BVO DHJ D- D-/R DQ 2; 1(3H)-Isobenzofuranone,3-bis(4-hydroxyphenyl)-; Phenolphthalein, 98.5%, pure, Indicator grade; 3, 3-Bis(p-hydroxyphenyl)-1(3H)-isobenzofuranone; Phenolphthalein [INN:BAN]; phenolphtalein; Figsen; Laxett es; Phenolphthalein [USP:INN:BAN]; FGT; Doxan (Salt/Mix); Phenolphthalein,white; Agoral (Salt/Mix); Modane (TN); Phenolphthalein,(S); Laxcaps (Salt/Mix); Phenolphthalein,yellow; Yellow phenolphthalein; PubChem7084; Phenolphthalein (INN); Spectrum_001077; Opera_ID_1337; Spectrum2_001279; Spectrum3_000888; Spectrum4_000982; Spectrum5_001268; Modane Plus (Salt/Mix); 3,3-bis(4-hydroxyphenyl)isobenzofuran-1-one; EC 201-004-7; Phenolphthalein ACS reagent; cid_4764; SCHEMBL27670; BSPBio_002518; KBioGR_001383; KBioSS_001557; Phenolphthalein, pH indicator; 5-18-04-00188 (Beilstein Handbook Reference); MLS001148397; BIDD:ER0202; DivK1c_000929; SPECTRUM1500480; Phenolphthalein Paper, DAB 6; SPBio_001278; ARONIS002962; BCBcMAP01_000174; HMS502O11; KBio1_000929; KBio2_001557; KBio2_004125; KBio2_006693; KBio3_001776; KS-00000YJD; Phenolphthalein solution, 0.1 N; NINDS_000929; HMS1920H04; HMS2091P06; HMS2236I09; HMS3374P06; LS-47; Pharmakon1600-01500480; component of Correctol (Salt/Mix); HY-D0211; KS-00003W2P; NSC10464; ZINC3831317; Phenolphthalein, p.a., ACS reagent; Tox21_110838; Tox21_202219; Tox21_300282; BBL002030; BDBM50077844; CCG-39112; NSC-10464; NSC215214; NSC757271; s5395; SBB008868; STK029876; AKOS000493033; Tox21_110838_1; CS-8152; DB04824; MCULE-5232154932; NE46883; NSC-215214; NSC-757271; IDI1_000929; SMP1_000235; NCGC00018200-01; NCGC00018200-02; NCGC00018200-03; NCGC00018200-04; NCGC00018200-05; NCGC00018200-06; NCGC00018200-08; NCGC00018200-09; NCGC00018200-10; NCGC00018200-12; NCGC00023694-03; NCGC00023694-04; NCGC00023694-05; NCGC00023694-06; NCGC00023694-07; NCGC00254039-01; NCGC00259768-01; AC-14431; AK130019; BP-30100; SC-74728; ST072636; VS-01000; SBI-0051481.P003; component of Feen-A-Mint Pills (Salt/Mix); TR-037762; 2-[Bis (4-hydroxyphenyl)methyl]benzoic acid; EU-0082600; FT-0659094; P0094; P0700; P0701; P0702; ST24041105; T8172; 3,3-bis(4-hydroxyphenyl)-2-benzofuran-1-on; EN300-92962; Phenolphthalein, SAJ first grade, >=97.0%; .alpha., .alpha.-Di(p-hydroxyphenyl)phthalide; 3,3-bis (4-hydroxyphenyl)-2-benzofuran-1-on; C14286; D05456; Phenolphthalein, JIS special grade, >=98.0%; AB00052070_15; Q187921; SR-01000000112; Q-201555; SR-01000000112-2; TRANSGENIC MODEL EVALUATION (PHENOLPHTHALEIN); 3,3-Bis(4-hydroxyphenyl)-2-benzofuran-1(3H)-one #; 3,3-Bis-(4-hydroxy-phenyl)-3H-isobenzofuran-1-one; BRD-K19227686-001-02-0; BRD-K19227686-001-12-9; Phenolphthalein solution, 1 % (w/v), pH 7.8-10.0; Z57233591; F0921-4309; TRANSGENIC MODEL EVALUATION II (PHENOLPHTHALEIN); Phenolphthalein solution, 0.04 % (w/v), pH 7.8-10.0; Phenolphthalein solution, 0.1 % (w/v), pH 7.8-10.0; Phenolphthalein solution, 0.5 wt. % in ethanol: water (1:1); Phenolphthalein, United States Pharmacopeia (USP) Reference Standard; InChI=1/C20H14O4/c21-15-9-5-13(6-10-15)20(14-7-11-16(22)12-8-14)18-4-2-1-3-17(18)19(23)24-20/h1-12,21-22; Phenolphthalein, ACS reagent, reag. Ph. Eur., indicator, 98-102% (calc. to the dried substance), S. No.: 879; Phenolphthalein, puriss., meets analytical specification of Ph??Eur., BP, 98-101% (calc. to the dried substance); Phenolphthalein; 5-18-04-00188 (Beilstein Handbook Reference)
Phenoxyethanol 2-Phenoxyethanol; 2-PHENOXYETHANOL; 122-99-6; Phenoxyethanol; Ethylene glycol monophenyl ether; Phenyl cellosolve; Ethanol, 2-phenoxy-; Phenoxytol; Phenoxethol; Phenoxetol; Ethylene glycol phenyl ether; Phenoxyethyl alcohol; 2-Phenoxyethan-1-Ol; 1-Hydroxy-2-phenoxyethane; Rose ether; Phenylmonoglycol ether; Arosol; Dowanol EP; 2-Phenoxyethyl alcohol; Glycol monophenyl ether; 2-Hydroxyethyl phenyl ether; Phenylglycol; Fenyl-cellosolve; 2-Fenoxyethanol; Dowanol EPH; 2-Phenoxy-ethanol; Emery 6705; Emeressence 1160; Fenylcelosolv; Marlophen P; beta-Hydroxyethyl phenyl ether; 2-phenoxy ethanol; Marlophen P 7; Spermicide 741; Tritonyl 45; Ethylan HB 4; EGMPE; Fenylcelosolv [Czech]; 2-Fenoxyethanol [Czech]; Fenyl-cellosolve [Czech]; Plastiazan-41 [Russian]; UNII-HIE492ZZ3T; NSC 1864; Polyoxyethylene phenol ether; Polyoxyethylene phenyl ether; Phenol-ethylene oxide adduct; MFCD00002857; Glycols, polyethylene, monophenyl ether; Phenoxyethanol [NF]; Polyethylene glycol phenyl ether; .beta.-Hydroxyethyl phenyl ether; HSDB 5595; PHE-G; PHE-S; 2-Phenoxyethanol, 99%; EINECS 204-589-7; FR 214; 9004-78-8; .beta.-Phenoxyethyl alcohol; alpha-Phenyl-omega-hydroxypoly(oxy-1,2-ethanediyl); BRN 1364011; HIE492ZZ3T; AI3-00752()C; CHEBI:64275; QCDWFXQBSFUVSP-UHFFFAOYSA-N; Phenoxyethanol (NF); Poly(oxy-1,2-ethanediyl), alpha-phenyl-omega-hydroxy-; NCGC00090731-01; NCGC00090731-05; DSSTox_CID_1976; DSSTox_RID_76437; DSSTox_GSID_21976; Erisept; Plastiazan-41; CAS-122-99-6; Phenol, ethoxylated; PHG; .beta.-Phenoxyethanol; phenylcellosolve; Phenoxyethanolum; CCRIS 9481; Ethylene glycol-monophenyl ether; Dalpad A; 2-phenyloxyethanol; Newpol EFP; 2-(phenoxy)ethanol; beta-Hydroxyphenetole; 2-phenoxy-1-ethanol; beta-phenoxyethylalcohol; ACMC-1BVYG; 2-Phenoxyethanol, 9CI; WLN: Q2OR; EC 204-589-7; SCHEMBL15708; 2-Phenoxyethanol, >=99%; 4-06-00-00571 (Beilstein Handbook Reference); KSC174Q0P; MLS002174254; ethyleneglycol monophenyl ether; Euxyl K 400 (Salt/Mix); 2-PHENOXYETHANOL 500ML; CHEMBL1229846; DTXSID9021976; CTK0H4807; Ethylene glycol mono phenyl ether; NSC1864; HMS2268A20; NSC-1864; STR04582; ZINC1577061; Tox21_111002; Tox21_113532; Tox21_202111; Tox21_300842; ANW-18088; BBL027410; LS-672; SBB060485; STK802556; 2-Phenoxyethanol, analytical standard; Fungal Terminator [veterinary] (TN); AKOS000118741; Tox21_111002_1; DB11304; MCULE-1828011376; RTR-003651; TRA0162661; NCGC00090731-02; NCGC00090731-03; NCGC00090731-04; NCGC00090731-06; NCGC00090731-07; NCGC00090731-08; NCGC00254745-01; NCGC00259660-01; Ethylene glycol monophenyl ether, >=90%; LS-72941; SC-47140; SMR000112131; ETHANOL,2-PHENOXY MFC8 H10 O2; ST2417151; TR-003651; FT-0613280; P0115; P1953; ST51046662; 2-Phenoxyethanol, tested according to Ph.Eur.; D08359; 97692-EP2287158A1; 97692-EP2305662A1; 97692-EP2372017A1; A805003; Q418038; SR-01000838345; J-510235; SR-01000838345-2; F1905-6997; Z426194440; Ethyleneglycol-monophenyl ether 100 microg/mL in Methanol; Ethylene glycol monophenyl ether, SAJ first grade, >=95.0%; Phenoxyethanol, European Pharmacopoeia (EP) Reference Standard; Phenoxyethanol, United States Pharmacopeia (USP) Reference Standard; InChI=1/C8H10O2/c9-6-7-10-8-4-2-1-3-5-8/h1-5,9H,6-7H; 2-Phenoxyethanol, Pharmaceutical Secondary Standard; Certified Reference Material; Ethanol, 2-phenoxy-; 4-06-00-00571 (Beilstein Handbook Reference)
Phentolamine 3-[[(4,5-Dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino]phenol; Phentolamine; C 7337
Phenylacetaldehyde Benzeneacetaldehyde; phenylacetaldehyde; 2-phenylacetaldehyde; 122-78-1; Benzeneacetaldehyde; Hyacinthin; Phenylethanal; alpha-Tolualdehyde; 2-Phenylethanal; Phenylacetic aldehyde; alpha-Toluic aldehyde; Oxophenylethane; Acetaldehyde, phenyl-; Benzylcarboxaldehyde; 1-Oxo-2-phenylethane; Phenacetaldehyde; phenyl acetaldehyde; phenyl-Acetaldehyde; Benzenacetaldehyde; UNII-U8J5PLW9MR; Phenylacetaldehyde (natural); .alpha.-Tolualdehyde; alpha-Phenylacetaldehyde; FEMA No. 2974; Benzacetaldehyde; NSC 406309; .alpha.-Toluic aldehyde; U8J5PLW9MR; EINECS 204-574-5; a-Tolyaldehyde; Acetaldehyde, phenyl- (8CI); AI3-02175; CHEBI:16424; DTUQWGWMVIHBKE-UHFFFAOYSA-N; DSSTox_CID_1483; DSSTox_RID_76177; DSSTox_GSID_21483; Phenylacetaldehyde, 98%, stabilized; CAS-122-78-1; benzeneethanal; a-Tolualdehyde; 2-phenylethanone; a-toluic aldehyde; alpha-Tolyaldehyde; Phenylacetoaldehyde; benzene acetaldehyde; a-Phenylacetaldehyde; 2-phenyl-acetaldehyde; PubChem19675; ACMC-209uaw; bmse000427; NCIOpen2_003602; Phenylacetaldehyde, >=90%; SCHEMBL18972; KSC174S9R; CHEMBL1233464; DTXSID3021483; CTK0H4998; ZINC895323; KS-00000V9N; STR00412; Tox21_201582; Tox21_302945; ANW-43542; MFCD00006993; NSC406309; s9357; SBB061710; AKOS000119316; CS-W011205; DB02178; HY-W010489; LS-3037; MCULE-3725701027; NSC-406309; RTR-003630; TRA0034790; Phenylacetaldehyde, >=95%, FCC, FG; NCGC00249076-01; NCGC00256522-01; NCGC00259131-01; SC-19014; DB-041686; TR-003630; FT-0631709; P0119; ST24041010; ST51047695; C00601; 11967-EP2272517A1; 11967-EP2287159A1; 11967-EP2301534A1; 11967-EP2305671A1; 11967-EP2308848A1; 11967-EP2311451A1; 11967-EP2311840A1; 11967-EP2316450A1; 11967-EP2374783A1; 11967-EP2377841A1; A804962; Q424998; Q-201558; F2190-0653; D60A2590-0A65-4BA8-A05B-D8423408535C; Phenylacetaldehyde solution, natural, 10 wt. % in ethanol, FG; InChI=1/C8H8O/c9-7-6-8-4-2-1-3-5-8/h1-5,7H,6H; Phenylacetaldehyde solution, technical, ~50% in diethyl phthalate; Phenylacetaldehyde; Acetaldehyde, phenyl-
Phenylacetic acid 4-09-00-01614 (Beilstein Handbook Reference)
Phenylboronic acid Phenyboric acid; Benzeneboronic acid; T-500
Phenylbutazone 4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione; Phenylbutazone; 50-33-9; 4-Butyl-1,2-diphenylpyrazolidine-3,5-dione; Butazolidine; Fenilbutazona; Butazolidin; Diphenylbutazone; Phenylbutazonum; Butapirazol; Butapyrazole; Butacote; Butadion; Bute; Alkabutazona; Butapirazole; Chembutazone; Fenibutazona; Fenylbutazon; Intrabutazone; Mephabutazon; Mephabutazone; Praecirheumin; Scanbutazone; Alqoverin; Anpuzone; Anuspiramin; Arthrizon; Artrizin; Artrizone; Artropan; Azobutyl; Bunetzone; Butacompren; Butadiona; Butagesic; Butalgina; Butalidon; Butarecbon; Butartril; Butartrina; Butazina; Butazona; Butidiona; Butylpyrin; Buvetzone; Digibutina; Diossidone; Diphebuzol; Ecobutazone; Eributazone; Febuzina; Fenartil; Fenibutal; Fenibutasan; Fenibutol; Fenilbutina; Fenilbutine; Fenilidina; Fenotone; Intalbut; Intrazone; Ipsoflame; Malgesic; Merizone; Nadazone; Nadozone; Novophenyl; Phebuzin; Phebuzine; Phenbutazol; Phenopyrine; Phenylbutaz; Phenyzone; Pyrabutol; Pyrazolidin; Rectofasa; Reumasyl; Reumazin; Reumazol; Reumuzol; Reupolar; Robizone; Rubatone; Alindor; Anerval; Antadol; Azolid; Benzone; Betazed; Busone; Butaluy; Butone; Diozol; Elmedal; Lingel; Reudox; Reumune; Butoz; Buzon; Kadol; Reudo; Butiwas-Simple; Neo-zoline; Phenyl-Mobuzon; Equi bute; Robizon-V; Phenylbutazon; Butaphen; Equipalazone; Flexazone; Ia-But; Pirarreumol B; Buta phen; 4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione; Bizolin 200; Fenilbutazon; Phenbutazone; Schemergin; Bizolin; Wescozone; Zolaphen; Azdid; Tazone; Uzone; Exrheudon N; Robizone-V; Phen-Buta-Vet; Butadionum; Schemergen; Shigrodin; Tencodyne; Tevcodyne; Therazone; Todalgil; Zolidinum; Tetnor; Ticinil; B.t.z.; 3,5-Pyrazolidinedione, 4-butyl-1,2-diphenyl-; esteve; 4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE; Phenyl butazone; Usaf ge-15; 4-Butyl-1,2-diphenyl-3,5-dioxopyrazolidine; Fenilbutazone [DCIT]; Phenylbutazon [German]; 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione; 3,5-Dioxo-1,2-diphenyl-4-N-butylpyrazolidine; VAC-10; A 7514; Fenilbutazona [INN-Spanish]; Phenylbutazonum [INN-Latin]; DA-192; 1,2-Diphenyl-4-butyl-3,5-pyrazolidinedione; 3,5-Dioxo-1,2-diphenyl-4-n-butyl-pyrazolidin; G 13,871; UNII-GN5P7K3T8S; 1,2-Diphenyl-3,5-dioxo-4-butylpyrazolidine; 1,2-Diphenyl-4-butyl-3,5-dioxopyrazolidine; R-3-ZON; CCRIS 2374; CHEBI:48574; HSDB 3159; 3,5-Dioxe-4 buty-1, diphenyl-pyrazolidine; NCI-C56531; EINECS 200-029-0; NSC 25134; G 13871; BRN 0290080; GN5P7K3T8S; MLS000069424; VYMDGNCVAMGZFE-UHFFFAOYSA-N; NCI-C55414; MFCD00005500; NCGC00015846-10; NCGC00015846-11; Fenilbutazone; Butatron; SMR000059073; DSSTox_CID_1136; DSSTox_RID_75967; DSSTox_GSID_21136; P1Z; Equiphen; fe nilbutine; butyl pyrin; art rizin; CAS-50-33-9; 4297-92-1; component of Azolid-A; 4-butyl-1,2-diphenyl-1,2-diazolidine-3,5-dione; SR-01; AZOLID (TN); Phenylbutazone [USAN:INN:BAN:JAN]; B.T.Z; Alkazone; Phenogel; Phenylbutazone/; Phen-Buta; 1,2-diphenyl-3,5-dioxo-4-n-butylpyrazoline; Pirarreumol 'B'; Phenylbutazone [USP:INN:BAN:JAN]; 1,5-dioxopyrazolidine; Spectrum_001079; 4-Butyl-1,5-dione; Phenylbutazone, 99+%; Opera_ID_888; 3,5-dioxo-4-butyl-1-diphenyl-pyrazolidine; Bute; Butazolidin; Butatron; Spectrum2_001282; Spectrum3_000675; Spectrum4_000477; Spectrum5_001335; Lopac-P-8386; P1686; Epitope ID:124940; P 8386; SCHEMBL3632; Lopac0_000993; Oprea1_416494; BSPBio_002369; KBioGR_000954; KBioSS_001559; KSC269K7B; MLS001148412; MLS002152929; DivK1c_000331; SPECTRUM1500482; SPBio_001283; 1,5-dioxo-4-butylpyrazolidine; 3, 4-butyl-1,2-diphenyl-; 4-Butyl-1,5-dioxopyrazolidine; 4-Butyl-1,5-pyrazolidinedione; GTPL7270; 1,3-dioxo-4-N-butylpyrazoline; DTXSID9021136; CTK1G9570; HMS501A13; KBio1_000331; KBio2_001559; KBio2_004127; KBio2_006695; KBio3_001589; KS-00000TLZ; NINDS_000331; Phenylbutazone (JP17/USP/INN); BCPP000108; HMS1920H06; HMS2090H17; HMS2091P08; HMS2233B13; HMS3263G07; HMS3369P16; HMS3649M17; HMS3651G15; HMS3715E21; LS-71; Pharmakon1600-01500482; Phenylbutazone, analytical standard; component of Azolid-A (Salt/Mix); BCP02607; HY-B0230; NSC25134; 3,2-diphenyl-4-N-butylpyrazolidine; Tox21_110242; Tox21_110243; Tox21_201809; Tox21_302763; Tox21_500993; 3,2-diphenyl-4-N-butyl-pyrazolidin; ABP000789; AC-683; CCG-39220; NSC-25134; NSC757272; s1654; SBB012526; STK388348; AKOS001592731; Phenylbutazone (Butazolidin, Butatron); Tox21_110242_1; ZINC100004227; CS-2180; DB00812; KS-5127; LP00993; MCULE-4303869118; NE30722; NSC-757272; SDCCGSBI-0050966.P005; WLN: T5VNNV EHJ BR& CR& E4; IDI1_000331; NCGC00015846-01; NCGC00015846-02; NCGC00015846-03; NCGC00015846-04; NCGC00015846-05; NCGC00015846-06; NCGC00015846-07; NCGC00015846-08; NCGC00015846-09; NCGC00015846-12; NCGC00015846-13; NCGC00015846-15; NCGC00023855-03; NCGC00023855-04; NCGC00023855-05; NCGC00023855-06; NCGC00023855-07; NCGC00023855-08; NCGC00181112-01; NCGC00256449-01; NCGC00259358-01; NCGC00261678-01; AK542945; SC-25755; ST066897; SBI-0050966.P004; AB2000198; DB-051755; EU-0100993; FT-0603217; SW199456-2; UNM000001255503; 1,2-diphenyl-3,5-dioxo-4-butyl-pyrazolidine; Phenylbutazone, SAJ special grade, >=99.0%; 1,2-diphenyl-3,5-dioxo-4-n-butylpyrazolidine; 4-Butyl-1,2 -diphenyl-3,5-dioxo pyrazolidine; 4-Butyl-1,2-diphenyl-3,5-dioxo pyrazolidine; C07440; D00510; 1,2-diphenyl-3,5-dioxo-4-n-butyl-pyrazolidine; AB00052071-15; AB00052071-16; AB00052071_17; AB00052071_18; A828072; AG-205/04675049; Q421342; SR-01-2; SR-01-4; SR-01-5; SR-01-9; W-105972; BRD-K10843433-001-12-8; BRD-K10843433-001-20-1; SR-01-13; Z57355370; 4-butyl-1,2-diphenyl-1H-pyrazole-3,5(2H,4H)-dione; Phenylbutazone, TraceCERT(R), certified reference material; Phenylbutazone, European Pharmacopoeia (EP) Reference Standard; Phenylbutazone, United States Pharmacopeia (USP) Reference Standard; InChI=1/C19H20N2O2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16/h4-13,17H,2-3,14H2,1H; Phenylbutazone; A 7514
Phenylephrine (alphaR)-3-Hydroxy-alpha-[(methylamino)methyl]benzenemethanol; Phenylephrine; AI3-02402
Phenylmalonic acid alpha-Carboxyphenylacetic acid
Phenylmethanesulphonic acid Benzenemethanesulfonic acid; Benzylsulfonic acid; 4-11-00-00485 (Beilstein Handbook Reference)
Phenylthiourea N-Phenylthiourea; Phenylthiourea; 1-Phenylthiourea; N-Phenylthiourea; 103-85-5; 1-PHENYL-2-THIOUREA; Phenylthiocarbamide; Thiourea, phenyl-; Phenyl-2-thiourea; Urea, 1-phenyl-2-thio-; phenyl-thiourea; Thiourea, N-phenyl-; Fenylthiomocovina; USAF EK-1569; alpha-Phenylthiourea; RCRA waste number P093; NCI-C02017; CCRIS 514; phenyl thiourea; Fenylthiomocovina [Czech]; NSC 5779; monophenyl thiourea; N-Phenyl-Thiourea; N-phenylisothiourea; U 6324; UNII-6F82C6Q54C; .alpha.-Phenylthiourea; HSDB 4105; EINECS 203-151-2; MFCD00004933; RCRA waste no. P093; AI3-07549; CHEMBL263376; CHEBI:46261; FULZLIGZKMKICU-UHFFFAOYSA-N; 6F82C6Q54C; DSSTox_CID_1134; DSSTox_RID_75965; DSSTox_GSID_21134; PTC; 1-Phenyl-2-thiourea, 97%; amino(phenylamino)methane-1-thione; CAS-103-85-5; URS; 1bug; Phenylthioharnstoff; phenyl 2-thiourea; N'-phenyl-thiourea; PhNHCSNH2; WLN: SUYZMR; PhNHC(S)NH2; N-Phenylthiourea, 97%; 2-thiourea, 1-phenyl-; PhNHC(=S)NH2; TimTec1_004784; N-Phenylthiourea, >=98%; SCHEMBL42753; KSC176O0D; ACMC-20989i; DTXSID9021134; CTK0H6701; KS-00000MCZ; EBD9082; NSC5779; HMS1547J10; NSC-5779; ZINC3875720; Tox21_201682; Tox21_302998; ANW-14980; BBL013021; BDBM50240041; LS-367; SBB036022; STK398097; AKOS000266872; ACN-049902; DB03694; MCULE-6207378439; RTR-000891; TRA0065303; NCGC00090967-01; NCGC00090967-02; NCGC00090967-03; NCGC00090967-04; NCGC00256507-01; NCGC00259231-01; AC-13462; AK305328; MS-20376; SC-22772; SC-64640; ST079820; TR-000891; FT-0608239; P0237; EN300-18229; VU0510645-1; L-2619; N-Phenylthiourea, Grade II, >=90% (HPLC); A800823; Q411216; J-001049; N-Phenylthiourea, PESTANAL(R), analytical standard; F3143-0088; InChI=1/C7H8N2S/c8-7(10)9-6-4-2-1-3-5-6/h1-5H,(H3,8,9,10; Phenylthiourea; U 6324
Phenytoin 5,5-Diphenyl-2,4-imidazolidinedione; phenytoin; 5,5-DIPHENYLHYDANTOIN; 57-41-0; Diphenylhydantoin; Dilantin; 5,5-diphenylimidazolidine-2,4-dione; Phenytoine; Dihydantoin; Aleviatin; Dilabid; Diphantoin; Diphenylan; Zentropil; Epamin; Diphedan; Fenylepsin; Lepitoin; Phentytoin; Sodanton; Difenin; Dihycon; Lehydan; Diphenylhydatanoin; Dantoinal; Di-Hydan; Dilantine; Dillantin; Diphenine; Diphentyn; Ditoinate; Elepsindon; Epilantin; Fenitoina; Fenytoine; Hidantilo; Hidantina; Hidantomin; Hydantoinal; Kessodanten; Phanantin; Phanatine; Phenatoine; Sodantoin; Sylantoic; Thilophenyl; Zentronal; Auranile; Dantinal; Dantoine; Difetoin; Difhydan; Dintoin; Dintoina; Diphedal; Diphenin; Enkelfel; Epifenyl; Epihydan; Fentoin; Hidantal; Hydantal; Idantoil; Idantoin; Labopal; Phentoin; Ritmenal; Saceril; Sanepil; Silantin; Solantin; Danten; Denyl; Epelin; Epinat; Epised; Eptal; Hidan; Lepsin; Ekko; Ictalis simple; Toin unicelles; Dilantin acid; Dantoinal klinos; Om-Hydantoine; Di-Phetine; Epdantoine simple; Hidantina vitoria; Gerot-epilan-D; Epilan-D; Neosidantoina; Comitoina; Hidantina senosian; Hydantol; Minetoin; Novantoina; Causoin; Convul; Di-Lan; Ekko capsules; Neos-Hidantoina; Om hidantoina simple; TOIN; Phenhydanin; Phenytex; Sinergina; Sodanthon; Iphenylhydantoin; Phenytoin-Gerot; 2,4-Imidazolidinedione, 5,5-diphenyl-; Difenilhidantoina; Fenytoin Dak; Didan TDC 250; Dilantin-125; Epdantoin Simple; Phenytoin AWD; Epilan D; Novophenytoin; Phenytoinum; Diphenat; Hindatal; Hydantin; Epanutin; Fenitoina [INN-Spanish]; Phenytoine [INN-French]; Phenytoinum [INN-Latin]; 5,5-Diphenyl-2,4-imidazolidinedione; Difenilhidantoina [Spanish]; Diphenylhydantoine [French]; Citrulliamon; 5,5-Dwufenylohydantoina; Antisacer; Phenitoin; Comital; Fenantoin Mn Pharma; Diphenylhydantoine; Di-Lan (VAN); Diphenylhydantoin (VAN); Diphentoin; DILANTIN-30; Solantoin; Solantyl; Eptoin; DPH (VAN); PHENYTEK; PHENYTOIN SODIUM; Fenidantoin "s"; 5,5-Diphenylimidazolidin-2,4-dione; 5,5-Diphenyl-imidazolidine-2,4-dione; 5,5-Diphenylhydantoin (IUPAC); Phenhydan; 5,5-Dwufenylohydantoina [Polish]; Hydantoin, 5,5-diphenyl-; Epasmir "5"; Didan-tdc-250; CCRIS 515; CHEBI:8107; NCI-C55765; 5,5-Diphenylhydantoin (phenytoin); UNII-6158TKW0C5; fenidantoin ''s''; epasmir ''5''; AI3-52498; CXOFVDLJLONNDW-UHFFFAOYSA-N; NSC 8722; Dilantin (TN); EINECS 200-328-6; MFCD00005264; MLS000069789; Extended Phenytoin Sodium; Fenitoin; 5,5-diphenyltetrahydro-1H-2,4-imidazoledione; Fenidantoin s; NSC8722; 6158TKW0C5; NSC-8722; Epasmir 5; HSDB 3160; NCGC00021139-03; SMR000059026; DSSTox_CID_541; 630-93-3; DSSTox_RID_75650; DSSTox_GSID_20541; 5,5-Diphenylhydantoin, 99+%; elepsi ndon; phenat ine; Dihydan toin; fen toin; taco sal; ictalis simp le; CAS-57-41-0; phenytoin (PHN); 5,5-diphenyl-1,3-diazolidine-2,4-dione; component of Mebroin; Phenytoin [USAN:INN:BAN:JAN]; SR-01000075211; IFLab1_000214; Fenidantoin 's'; Dilantin,Phenytoin; PHENYTOIN SODIUM, EXTENDED; Episar (Salt/Mix); Epasmir '5'; Aladdin (Salt/Mix); Alepsin (Salt/Mix); Epsolin (Salt/Mix); Phenytoin (Lepitoin); Tacosal (Salt/Mix); Phenytoin [USAN:USP:INN:BAN:JAN]; Antisacer (Salt/Mix); Epdantoin (Salt/Mix); Epileptin (Salt/Mix); Hydantoin,5-diphenyl-; Spectrum_001105; Fenigramon (Salt/Mix); 5,5-diphenyl hydantoin; Citrullamon (Salt/Mix); Opera_ID_394; PHENYTOIN (5,5-DIPHENYLHYDANTOIN); 2, 5,5-diphenyl-; CHEMBL16; Spectrum2_001281; Spectrum3_000890; Spectrum4_000984; Spectrum5_001369; Lopac-D-4007; ACMC-1AMO9; Epitope ID:117723; D 4007; SCHEMBL3440; BIDD:PXR0090; Lopac0_000329; Lopac0_000378; Oprea1_373280; BSPBio_001437; KBioGR_001387; KBioSS_001585; KSC493O2R; MLS001074087; MLS002454401; BIDD:GT0625; DivK1c_000507; Soluble phenytoin (Salt/Mix); 3-(4-iodophenyl)acrylic acid; SPBio_001281; Phenytoin (JP17/USP/INN); GTPL2624; 2-hydroxy-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one; DTXSID8020541; CTK3J3728; KBio1_000507; KBio2_001585; KBio2_004153; KBio2_006721; KBio3_001780; WLN: T5MVMV EHJ ER& ER; 5,5-Diphenylhydantoin, >=99%; NINDS_000507; Phenytoin 1.0 mg/ml in Methanol; SM-88 COMPONENT PHENYTOIN; HMS1412J16; HMS1694O05; HMS1791H19; HMS1989H19; HMS2089E11; HMS2236J06; HMS3261K17; HMS3402H19; HMS3657O03; BCP05960; HY-B0448; Hydantoin, 5,5-diphenyl- (8CI); KS-00000C9F; ZINC2510358; Tox21_110861; Tox21_202299; Tox21_300281; Tox21_500378; AC-376; ANW-32714; BBL027509; BDBM50003655; BDBM50101816; s2525; SBB057224; STK058029; STK182871; STL454130; AKOS000416887; AKOS003245432; Tox21_110861_1; 5,5-diphenylimidazolidine-2,4-dione.; CCG-104011; CCG-221682; CS-2559; DB00252; LP00378; MCULE-2376673346; NE10390; RTR-037347; TRA0089622; 5,5-di(phenyl)imidazolidine-2,4-dione; IDI1_000507; IDI1_008433; NCGC00015342-01; NCGC00015342-02; NCGC00015342-03; NCGC00015342-04; NCGC00015342-05; NCGC00015342-06; NCGC00015342-07; NCGC00015342-08; NCGC00015342-09; NCGC00015342-10; NCGC00021139-01; NCGC00021139-02; NCGC00021139-04; NCGC00021139-05; NCGC00021139-06; NCGC00021139-07; NCGC00021139-08; NCGC00021139-09; NCGC00021139-10; NCGC00021139-11; NCGC00091492-01; NCGC00091492-02; NCGC00091492-03; NCGC00091492-04; NCGC00091492-05; NCGC00093810-01; NCGC00093810-02; NCGC00254135-01; NCGC00259848-01; NCGC00261063-01; 5,5-?Diphenyl-?2,4-?imidazolidinedione; CPD000059026; SAM002554893; SC-16138; SC-39400; 5,5-Diphenyl-1H-imidazolidine-2,4-dione; AB1000452; TR-037347; D0894; EU-0100378; FT-0699999; P-235; ST45024762; SW203757-2; EN300-16818; C07443; D00512; 2,4-Imidazolidinedione, 5,5-diphenyl- (9CI); 5,5-diphenyl-1H-imidazole-2,4(3H,5H)-dione; AB00374253-10; AB00374253-11; AB00374253_13; A831435; Q410400; SR-01000003141; SR-01000003141-8; SR-01000075211-2; W-105468; BRD-K55930204-001-02-7; BRD-K55930204-236-11-0; Z56786458; 4-hydroxy-5,5-diphenyl-1,5-dihydro-2H-imidazol-2-one; F0020-1370; Phenytoin, European Pharmacopoeia (EP) Reference Standard; Phenytoin, United States Pharmacopeia (USP) Reference Standard; 5,5-Diphenylhydantoin solution, drug standard, 1.0 mg/mL in methanol; Phenytoin, Pharmaceutical Secondary Standard; Certified Reference Material; Phenytoin for system suitability, European Pharmacopoeia (EP) Reference Standard; Phenytoin solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; InChI=1/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19; Phenytoin; AI3-52498
Phloretin 3-(4-Hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-1-propanone; phloretin; 60-82-2; Dihydronaringenin; 3-(4-Hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one; Phloretol; 1-Propanone, 3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-; NSC 407292; 3-(4-Hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-1-propanone; UNII-S5J5OE47MK; MFCD00002288; CCRIS 7459; beta-(p-Hydroxyphenyl)phloropropiophenone; 2',4',6'-Trihydroxy-3-(p-hydroxyphenyl)propiophenone; 2',4',6'-Trihydroxy-3-(4-Hydroxyphenyl)propiophenone; C15H14O5; EINECS 200-488-7; NSC407292; S5J5OE47MK; beta-(p-Hydroxyphenyl)-2,4,6-trihydroxypropiophenone; CHEMBL45068; CHEBI:17276; VGEREEWJJVICBM-UHFFFAOYSA-N; Phloretin, 98%; beta-(4-Hydroxyphenyl)-2,4,6-trihydroxypropiophenone; Propiophenone, 2',4',6'-trihydroxy-3-(p-hydroxyphenyl)-; 2',4,4',6'-Tetrahydroxydihydrochalcone; AK162403; .beta.-(p-Hydroxyphenyl)phloropropiophenone; 2',4,4',6'-Tetrahydroxy-Dihydrochalcone; Q-100701; SMR000326783; SR-01000076081; 2uxi; G50; Spectrum_001295; 4,2',4',6'-Tetrahydroxydihydrochalcone; Phloretin, >=99%; ACMC-209mmd; SpecPlus_000333; Spectrum2_000681; Spectrum3_001036; Spectrum4_001172; Spectrum5_001698; Lopac-P-7912; DSSTox_CID_2393; cid_4788; DSSTox_RID_76569; DSSTox_GSID_22393; Lopac0_001012; Oprea1_824722; REGID_for_CID_4788; SCHEMBL38131; BSPBio_002851; KBioGR_001803; KBioSS_001775; SPECTRUM300554; MLS000728507; MLS000859922; MLS006012024; BIDD:ER0174; DivK1c_006429; SPBio_000801; GTPL4285; DTXSID6022393; BCBcMAP01_000040; BDBM23446; CTK3J2061; KBio1_001373; KBio2_001775; KBio2_004343; KBio2_006911; KBio3_002071; ZINC47553; HMS2224N17; HMS3263K05; HMS3332J03; HMS3656I07; ACN-S003569; BCP28296; HY-N0142; KS-00000C3P; TNP00255; Tox21_202854; Tox21_501012; 2′ ,4′ ,6′ -Trihydroxy-3-p-hydroxyphenylpropiophenone; ANW-33587; BBL027375; CCG-38573; CP0082; KM0437; LMPK12120525; O1P165; s2342; SBB066137; STL372996; AKOS015856338; AC-7995; ACN-035397; CS-1477; DB07810; LP01012; MCULE-3672992389; NSC-407292; RTR-031371; SDCCGMLS-0066637.P001; SDCCGSBI-0050985.P003; TRA0006136; CAS-60-82-2; Phloretin, analytical reference material; SMP1_000238; NCGC00015840-01; NCGC00015840-02; NCGC00015840-03; NCGC00015840-04; NCGC00015840-05; NCGC00015840-06; NCGC00015840-07; NCGC00015840-08; NCGC00015840-09; NCGC00094304-01; NCGC00094304-02; NCGC00094304-03; NCGC00094304-04; NCGC00260400-01; NCGC00261697-01; AS-14100; CC-33738; SC-18405; ST057164; SY017103; AB0016775; AX8147786; DB-053714; LS-187222; LS-188085; TR-031371; EU-0101012; FT-0603256; N1316; P1966; ST24041477; SW219308-1; C00774; P 7912; C-17278; 2',6'-Trihydroxy-3-(p-hydroxyphenyl)propiophenone; Q2268463; SR-01000076081-1; SR-01000076081-7; SR-01000076081-8; .beta.-(p-Hydroxyphenyl)-2,6-trihydroxypropiophenone; BRD-K15563106-001-02-4; BRD-K15563106-001-10-7; Propiophenone,4',6'-trihydroxy-3-(p-hydroxyphenyl)-; .beta.-(p-Hydroxyphenyl)-2,4,6-trihydroxypropiophenone; 2',4',6'-Trihydroxy-3-(4-hydroxyphenyl)-propiophenone; 1-(2,4,6-trihydroxyphenyl)-3-(4-hydroxyphenyl)-1-propanone; 3-(4-Hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-1-propanon; 3-(4-Hydroxy-phenyl)-1-(2,4,6-trihydroxy-phenyl)-propan-1-one; Propiophenone, 2',4',6'-trihydroxy-3-(p-hydroxyphenyl)- (8CI); InChI=1/C15H14O5/c16-10-4-1-9(2-5-10)3-6-12(18)15-13(19)7-11(17)8-14(15)20/h1-2,4-5,7-8,16-17,19-20H,3,6H; Phloretin; CCRIS 7459
Phloroglucinol 1,3,5-Benzenetriol; phloroglucinol; 108-73-6; Benzene-1,3,5-triol; 1,3,5-trihydroxybenzene; 1,3,5-benzenetriol; Phloroglucin; Phloroglucine; Spasfon-Lyoc; s-Trihydroxybenzene; 5-Hydroxyresorcinol; Benzene-s-triol; 3,5-Dihydroxyphenol; Benzene, trihydroxy; sym-Trihydroxybenzene; 5-Oxyresorcinol; Dilospan S; Phloroglucinol anhydrous; Floroglucinol; Floroglucin; 5-Oxyresorcinolphloroglucin; 1,3,5-THB; 1,3,5-Trihydroxycyclohexatriene; 1,3,5-Triol; Floroglucin [Czech]; Floroglucinol [Czech]; Benzene, 1,3,5-trihydroxy-; UNII-DHD7FFG6YS; 5-Benzenetriol; NSC 1572; CCRIS 4147; Phloroglucinol (JAN); DHD7FFG6YS; Phloroglucinol, anhydrous; 1,2,5-trihydroxybenzene; EINECS 203-611-2; MFCD00002286; BRN 1341907; AI3-08848; CHEMBL473159; CHEBI:16204; QCDYQQDYXPDABM-UHFFFAOYSA-N; NSC-1572; Phloroglucinol, 99+%, anhydrous; NCGC00166270-01; phloroglucinol ts; 1,5-Benzenetriol; 13X; Dilospan S (TN); PubChem2603; Phloroglucinol [BAN]; 1,5-Trihydroxybenzene; 1,5-Triol; Benzene,3,5-trihydroxy-; WLN: QR CQ EQ; 1,3,5-trihydroxylbenzene; 1,3,5-trihydroxy benzene; 1,3,5-trihydroxy-benzene; 1,3, 5-Trihydroxybenzene; SCHEMBL26311; 1,5-Trihydroxycyclohexatriene; 4-06-00-07361 (Beilstein Handbook Reference); KSC174Q3J; Phloroglucinol, p.a., 99%; DTXSID9048354; CTK0H4834; KS-00000VUQ; NSC1572; ZINC391883; ACT13446; ANW-15974; BBL018701; BDBM50249069; STL146346; phloroglucinol (1,3,5-benzenetriol); Phloroglucinol, >=99.0% (HPLC); AKOS000119851; AM84333; AS04650; DB12944; FS-4574; MCULE-5869131240; RTR-001989; TRA0078596; 1,3,5-Benzenetriol (ACD/Name 4.0); NCGC00166270-02; AC-10081; SC-00309; AB1004109; LS-105905; TR-001989; FT-0606511; P0249; P1376; ST50214381; A-8565; C02183; D00152; A801919; Q899008; Q-200070; Phloroglucinol, plant cell culture tested, BioReagent; F0001-0177; Phloroglucinol, Used to detect the presence of wood fiber.; InChI=1/C6H6O3/c7-4-1-5(8)3-6(9)2-4/h1-3,7-9; 1,3,5-Trihydroxybenzene; 1,3,5-Trihydroxybenzene anhydrous; 1,3,5-THB; Phloroglucinol (anhydrous), European Pharmacopoeia (EP) Reference Standard; 1,3
Phosphocreatine N-[Imino(phosphonoamino)methyl]-N-methylglycine; phosphocreatine; Creatine phosphate; phosphorylcreatine; N-phosphocreatine; fosfocreatine; N-(Phosphonoamidino)sarcosine; 67-07-2; N-Phosphorylcreatine; creatine-P; Creatinephosphoric acid; UNII-020IUV4N33; C4H10N3O5P; Creatine phosphic acid; EINECS 200-643-9; N-(N-Phosphonoamido)sarcosine; N-(phosphonoamidino)-Sarcosine; CHEBI:17287; 020IUV4N33; Glycine, N-(imino(phosphonoamino)methyl)-N-methyl-; Glycine, N-[imino(phosphonoamino)methyl]-N-methyl-; N-[imino(phosphonoamino)methyl]-N-methylglycine; W-104734; N-Phosphorocreatine; [[imino(phosphonoamino)methyl](methyl)amino]acetic acid; {[imino(phosphonoamino)methyl](methyl)amino}acetic acid; Neoton; N(omega)-Phosphonocreatine; bmse000079; 2-[methyl-(N'-phosphonocarbamimidoyl)amino]acetic acid; CHEMBL1204644; DTXSID0058776; DRBBFCLWYRJSJZ-UHFFFAOYSA-N; HY-D0885; KM1062; STL452993; AKOS027340220; DB13191; AS-12479; LS-176562; CS-0013742; N-methyl-N-(N-phosphonocarbamimidoyl)glycine; C02305; N-[imino(phosphonoamino)methyl]-N-methyl-Glycine; 067C072; 2-(1-methyl-3-phosphonocarbamimidamido)acetic acid; Phosphocreatine; EINECS 200-643-9
Phosphoenolpyruvate 2-(Phosphonooxy)-2-propenoic acid; 2-Propenoic acid, 2-(phosphonooxy)-; Acrylic acid, 2-hydroxy-, dihydrogen phosphate
Phosphoglycolipids Bambermycin; Flavomycin